Catalytic Double Cyclization Process for Antitumor Agents against Breast Cancer Cell Lines

Significant antitumor activity against breast cancer cells, including the most aggressive MDA-MB-231 and MDA-MB-468 cells

Treatment with dihydrofurofuranone 2l induces parp-1 cleavage in breast cancer cells: Western blot analyses of parp-1 in MCF-7 (A), MDA-MB-231 (B) and MDA-MB-468 (C) with GAPDH used as a loading control

HIGHLIGHTS

- Novel catalytic double cyclization method leading to bicyclic heterocycles in one step
- Direct synthesis of antitumor agents from simple substrates (4-yne-1,3-diols and CO)
- Identification of a new class of antitumor agents against breast cancer (BC) cells
- Significant antitumor activity against the most aggressive triple-negative BC cells
Catalytic Double Cyclization Process for Antitumor Agents against Breast Cancer Cell Lines

Raffaella Mancuso, Ida Ziccarelli, Adele Chimento, Nadia Marino, Nicola Della Ca’, Rosa Sirianni, Vincenzo Pezzi, and Bartolo Gabriele

SUMMARY
The development of efficient synthetic strategies for the discovery of novel antitumor molecules is a major goal in current research. In this context, we report here a catalytic double cyclization process leading to bicyclic heterocycles with significant antitumor activity on different human breast cancer (BC) cell lines. The products, 6,6a-dihydrofuro[3,2-b]fur-an-2(5H)-ones, were obtained in one step, starting from simple substrates (4-yne-1,3-diols, CO, and O2), under the catalytic action of PdI2 in conjunction with KI. These compounds have significant antiproliferative activity in vitro on human BC cell lines, both hormone receptor positive (MCF-7) and triple negative (triple-negative breast cancer [TNBC]; MDA-MB-231 and MDA-MB-468), while exhibiting practically no effects on normal BC cell lines, both hormone receptor positive (MCF-7) and triple negative (triple-negative breast cancer [TNBC]; MDA-MB-231 and MDA-MB-468), while exhibiting practically no effects on normal MCF-10A (human mammary epithelial) and 3T3-L1 (murine fibroblasts) cells. Thus, these compounds have the potential to expand the therapeutic options against BC, and in particular, against its most aggressive forms (TNBCs). Moreover, the present synthetic approach may provide an economic benefit for their production.

INTRODUCTION
Breast cancer (BC) is the leading cause of cancer death in women worldwide (Siegel et al., 2016, 2017), particularly in developed countries. Genetic factors, such as mutations of tumor suppressor genes BRCA1 and BRCA2; endocrine factors (such as estrogen exposure); as well as environmental and dietary factors may be involved in the onset of this disease. Several studies of gene expression profile have been performed to characterize BCs in different molecular subtypes, which may have a prognostic value (Voduc et al., 2010). An important classification can be made on the basis of specific receptor expression. Indeed, BCs are divided into hormone receptor (HR)-negative (HR–) and HR-positive (HR+) tumors. The latter group includes estrogen receptor (ER)-positive (ER+), progesterone receptor (PR)-positive (PR+), and human epidermal growth factor receptor 2 (HER2)-positive (HER2+) tumors, whereas HR– tumors include the so-called triple-negative breast cancers (TNBCs), which lack the expression of the three receptor types (Kirkpatrick, 2009). Although the survival rate at 5 years for treated patients with early-stage BC is extremely high, some subgroups of patients with advanced-stage BC may have recurrence within 10 years of treatment. The recurrence rate for HR+ tumors appears to be lower (recurrence rate is 8%) compared with that of the subtypes overexpressing HER2 or that have a triple-negative phenotype (recurrence rate is 15%–20%) (Haffty et al., 2006; Millar et al., 2009; Nguyen et al., 2008).

The selective ER modulator (SERM) tamoxifen and aromatase inhibitors (anastrozole, letrozole) are used for the treatment of tumors expressing steroid HRs, while trastuzumab (Herceptin), a monoclonal antibody that targets HER2, is used for the treatment of HER2+ tumors. TNBCs are particularly dangerous, because they are associated with an unfavorable prognosis (Bauer et al., 2007; Carey et al., 2007; Haffty et al., 2006) and because patients with TNBC derive no benefit from molecularly targeted regimens employing endocrine-based therapy or trastuzumab (Kirkpatrick, 2009). Classical chemotherapy aims to block cell proliferation, which, however, does not discriminate cancer cells from rapidly dividing normal cells within the organism. Therefore, new therapeutic approaches resulting from the discovery of new compounds with antitumor activity against TNBCs are still highly desirable.

In this work, we report an unprecedented catalytic double cyclization process leading to a new class of bicyclic heterocycles (dihydrofurofuranone derivatives) with significant antitumor activity in vitro against BC cell
lines, both HR+ (MCF-7) and TNBCs (MDA-MB-231 and MDAMB-468), while exhibiting practically no effects on normal MCF-10A (human mammary epithelial) and 3T3-L1 (murine fibroblasts) cells. These new compounds have therefore the potential to expand the therapeutic options against BC, in particular against its most aggressive forms (TNBCs).

RESULTS AND DISCUSSION
Palladium-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,3-diols Leading to Dihydrofurofuranones

Catalytic cyclization processes have recently attracted great interest in the chemistry scientific community owing to the possibility to synthesize in one step high-value-added molecules starting from simple building blocks, by their ordered sequential activation by the catalytic center (Alcaide and Almendros, 2014; Debrouwer et al., 2015; Guo et al., 2011; Krause and Winter, 2011; Tanaka and Tajima, 2012; Valera and Saa, 2016; Vlaar et al., 2011; Ye and Ma, 2014). Among the raw starting materials, carbon monoxide represents a simple and largely available C-1 unit, and its catalytic activation may allow to directly introduce a carbonyl functional group into an organic substrate in a highly atom-economical and efficient manner. In fact, carbonylation reactions are currently known to play a major role in the direct synthesis of carbonyl compounds both in industry and in the production of fine chemicals (Beller, 2006; Friis et al., 2016; Gabriele et al., 2012; Gadge and Bhanage, 2014; Gehrtz et al., 2016; Kalck and Urrutioýty, 2015; Kollar, 2008; Liu et al., 2011; Omae, 2011; Peng et al., 2017; Shen and Wu, 2017; Wu and Neumann, 2012; Wu et al., 2013a, 2013b, 2014; Wu, 2016; Wu and Beller, 2016).

In this work, we have developed an unprecedented carbonylative oxidative double cyclization process, which allows synthesizing bioactive, high-value-added bicyclic heterocycles (dihydrofurofuranone derivatives 2) starting from readily available 4-yne-1,3-diols 1; CO; and O2 (Scheme 1). In this reaction, the alkynediol, carbon monoxide, and oxygen are sequentially activated through the catalytic action of a very simple system (consisting of PdI2 in conjunction with an excess of KI) (Gabriele et al., 2014; Mancuso et al., 2014, 2015, 2016; Veltri et al., 2015, 2016a, 2016b, 2018), with the formation of two cycles and three new bonds (O-C, C-C, and C-O) in one single operation and in ordered sequence. It should be noted that, although an analogous process was reported for 4-ene-1,2-diols under different reaction conditions (Kapitán and Gracza, 2008), no previous example exists in the literature for the direct carbonylative double cyclization of 4-yne-1,3-diols leading to dihydrofurofuranones.

We started our investigation by studying the reaction between 3-methylnon-4-yne-1,3-diol 1a and carbon monoxide using 2 mol % PdI2 and 10 mol % KI, under 40 atm of a 4:1 mixture of CO and air in MeOH as the solvent (0.05 mmol of 1a per mL of MeOH) at 100°C. After 15 hr reaction time, 3-butyl-6a-methyl-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one 2a was isolated in 30% yield following chromatographic purification (unidentified heavy by-products accounted for substrate total conversion). The yield of 2a did not improve by changing the operative reaction conditions (data not shown); however, its formation confirmed the possibility to realize a previously unreported carbonylative double cyclization process starting from a 4-yne-1,3-diol in one step under catalytic conditions. The result was noteworthy, considering the different possible competitive pathways that could have been followed under carbonylation conditions by an alkynediol such as 1a (formation of cyclic carbonates, maleic esters, monocyclic β- or γ-lactones, and so on) (Beller, 2006; Kollár, 2008; Gabriele et al., 2012; Wu et al., 2013a; Wu and Beller, 2016). The catalytic process may be interpreted as occurring through an ordered sequence of mechanistic stages, involving (1) 5-exo-dig cyclization, via intramolecular nucleophilic attack of the hydroxyl group at C-1 to the triple bond coordinated to PdI2; (2) carbon monoxide insertion into the Pd-C bond of the ensuing vinylpalladium intermediate; (3) intramolecular trapping of the ensuing acylpalladium species by the hydroxyl at C-3, with further cyclization and nucleophilic displacement of palladium.
leading to the final bicyclic product and Pd(0); and (4) reoxidation of Pd(0) back to PdI$_2$ by oxygen in the presence of the 2 mol HI formally eliminated during the previous cyclization steps (Scheme 1; anionic iodide ligands are omitted for clarity).

We then tested the reactivity of a similar substrate, still bearing a butyl group on the triple bond, but with geminal methyl substituents at C-1. The reaction of 2,4-dimethyl dec-5-yne-2,4-diol $1b$ led to the corresponding dihydrofurofuranone $2b$ in a higher isolated yield with respect to $2a$, most probably due to the effect exerted by the geminal alkyl groups, which is known to favor cyclization processes (Jung and Piizi, 2005; Sammes and Weller, 1995). A 40% yield of $2c$ was obtained starting from alkynyldiol $1c$, bearing a sterically demanding tert-butyl group on the triple bond. On the other hand, 2,4-dimethyl-6-phenylhex-5-yne-2,4-diol $1d$, substituted with a phenyl group on the triple bond, afforded the corresponding dihydrofuranone $2d$ in 33% yield (Scheme 2).

A significant increase in product yield was observed when the triple bond was substituted with a trimethylsilyl group. Thus, 3-methyl-5-(trimethylsilyl)pent-4-yne-1,3-diol $1e$, under conditions similar to those previously employed for $1a$, led to the dihydrofurofuranone $2e$ in 72% yield after 3 hr reaction time (Figure 1). Other differently substituted substrates $1f$–$m$, still bearing the trimethylsilyl group (TMS) on the triple bond, behaved similarly, and afforded the corresponding dihydrofuranones $2f$–$m$ in fair to excellent yields (58%–94%, Figure 1). The structure of dihydrofurofuranone $2g$ was also confirmed by X-ray diffraction analysis (for details see Figure S1, Table S1, Transparent Methods, and cif file for $2g$, Data S1).

In the case of alkynediols $1i$–$k$, the substrates employed were a mixture of $2RS,4SR$ and $2RS,4RS$ diastereomers. To assess the different performances of the two diastereomers in the double cyclization process, we tested them independently after chromatographic separation. The reactions of the single diastereomers could also allow isolating the corresponding diastereomeric products, considering that the process is stereospecific. The results obtained are shown in Table 1. As can be seen from Table 1, the $2RS,4RS$ diastereomer was the most productive isomer (in terms of yield obtained for the corresponding dihydrofurofuranone) in the case of $1i$ and especially $1k$, whereas in the case of $1l$ a slightly higher yield was observed starting from the $2RS,4SR$ diastereoisomer. The structure of (5$RS,6aRS$)-$2j$ was unequivocally established by X-ray diffraction analysis (for details, see Figure S2, Table S2, Transparent Methods, and cif file for 5$RS,6aRS$-$2j$, Data S2), which also permitted to corroborate (owing to the stereospecificity of the reaction) the $2RS,4RS$ stereochemistry of the starting material $1j$.  

Scheme 2. Formation of Dihydrofurofuranones $2a$–d by PdI$_2$-Catalyzed Carbonylative Oxidative Double Cyclization of 4-Yne-1,3-diols $1a$–d

Anionic iodide ligands are omitted for clarity. See Transparent Methods for experimental details.
To further expand the synthetic scope of the reaction, we also attempted the desilylation of some representative silylated dihydrofurofuranones. Thus, crude products 2h, 2l, and 2m, deriving from carbonylation of 1h, 1l, and 1m, respectively, were treated, without further purification, with tetrabutylammonium fluoride (TBAF)‧H2O in THF at room temperature for 2 hr. As shown in Scheme 3, the corresponding...
desilylated furofuranone derivatives were obtained in good to high yields over the two steps (85%, 79%, and 61% based on starting 1h, 1l, and 1m, respectively).

**Antiproliferative Activity In Vitro of the Newly Synthesized Dihydrofurofuranones on MCF-7, MDA-MB-231, and MDA-MB-468 Human Breast Cancer Cell Lines**

Some of the newly synthesized dihydrofurofuranones have shown significant antiproliferative activity in vitro on human breast adenocarcinoma cell lines, including the most dangerous triple-negative ones (MDA-MB-231 and MDAMB-468). Although several furanone derivatives were previously described to possess antitumor properties (for a recent example, see Wu et al., 2017), the possible anticancer activity of bicyclic dihydrofurofuranones such as 2 has not been reported so far. The effects on tumor cell viability of different concentrations (1, 5, 10, 20, 40 μM) of five 6,6α-dihydrofuro[3,2-b]furan-2-(5H) derivatives (2d, 2e, 2g, 2l, and 3l) have been evaluated against MCF-7, MDA-MB-231, and MDAMB-468 BC cell lines (Figure 2); normal breast epithelial cells MCF-10A; and immortalized fibroblasts 3T3-L1 (Figure 3). In particular, for 2d a significant reduction in vitality of MCF-7 and MDA-MB231 was observed from 10 μM onward, whereas MDA-MB468 was slightly more sensitive and a significant reduction was obtained from the dose of 5 μM (Figure 2A). Compound 2g decreased the cell viability of all three cell lines from the lowest dose of 1 μM (Figure 2B). Compound 2e significantly affected the cell viability of TNBC cell lines from 5 μM, whereas it was effective from 10 μM on MCF-7 cells (Figure 2C). Product 2l also decreased MCF-7 (1–40 μM), MDA-MB-231, and MDA-MB-468 (10–40 μM) cell viability (Figure 2D). Dihydrofurofuranone 3l caused a modest but significant effect on MCF-7 (5–40 μM) and MDA-MB-231 (20–40 μM) cells, and was slightly more effective on MDA-MB-468, with the highest dose (40 μM) reaching almost a 40% inhibition (Figure 2E).

These data indicate that among all tested cell lines MDA-MD-468 appears more sensitive to all

**Table 1. Experiments with Single Diastereomers**

*Reaction conditions: alkyne 1 (0.25–0.5 mmol), PdI₂ (2 mol%), KI (10 mol%), CO (32 atm), air (8 atm), MeOH (5–10 mL), 100°C, 3–15 hr. See Transparent Methods for details.

| Entry | 1           | Time (h) | 2           | Yield of 2b |
|-------|-------------|----------|-------------|-------------|
| 1     | (2RS,4SR)-1i | 8        | (5RS,6aSR)-2i | 52          |
| 2     | (2RS,4SR)-1i | 3        | (5RS,6aSR)-2i | 61          |
| 3     | (2RS,4SR)-1j | 15       | (5RS,6aSR)-2j | 68          |
| 4     | (2RS,4SR)-1j | 8        | (5RS,6aSR)-2j | 52          |
| 5     | (2RS,4SR)-1k | 5        | (5RS,6aSR)-2k | 40          |
| 6     | (2RS,4SR)-1k | 3        | (5RS,6aSR)-2k | 80          |

Scheme 3. Synthesis of Desilylated Dihydrofurofuranones 3h, 3l, and 3m by PdI₂-Catalyzed Carbonylative Double Cyclization of 4-Yne-1,3-diols 1h, 1l, and 1m, Respectively, Followed by TBAF-induced Desilylation of the Crude Carbynylation Product

See Transparent Methods for experimental details.
compounds. This event could rely on a different pattern of gene expression present in these cells. A clear definition of target genes will help to explain such a difference.

To exclude the toxic effects of these compounds, experiments using normal breast epithelial cells MCF-10A and immortalized fibroblasts 3T3-L1 have been performed. As shown in Figure 3, the proliferative behavior of these cells is not affected by all doses of \(2d\) (Figure 3A), \(2g\) (Figure 3B), \(2e\) (Figure 3C), \(2l\) (Figure 3D), and \(3l\) (Figure 3E) for 72 hr. Cell viability was evaluated by MTT (MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Results were expressed as mean ± SD of three independent experiments each performed in triplicate. Statistically significant differences are indicated (*p < 0.05 versus basal). See Transparent Methods for experimental details. SD, standard deviation.

Figure 2. Dihydrofurofuranes 2d, 2e, 2g, 2l, and 3l Decrease Breast Cancer Cell Viability

(A–E) MCF-7, MDA-MB-231 and MDA-MB-468 cells were left untreated (0) or treated with different doses (1–40 \(\mu\)M) of \(2d\) (A), \(2g\) (B), \(2e\) (C), \(2l\) (D), and \(3l\) (E) for 72 hr. Cell viability was evaluated by MTT assay. Results were expressed as mean ± SD of three independent experiments each performed in triplicate. Statistically significant differences are indicated (*p < 0.05 versus basal). See Transparent Methods for experimental details. SD, standard deviation.
Taken together, the results obtained indicate that, among all compounds, 5,5-dimethyl-6a-phenyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one 2l is the one with the most significant inhibitory effects on the cell vitality of tumor cells, whereas it has little or no effect on the vitality of normal cells. This prompted us to investigate the molecular mechanism behind the 2l-dependent decrease of BC cell viability. To this aim, we performed assays aimed to investigate if 2l initiated an apoptotic mechanism in MCF-7 and MDA-MB-231 and MDA-MB-468 cells. Apoptosis is an energy-dependent process characterized by a number of hallmarks, such as membrane blebbing, nuclear chromatin condensation, cell shrinkage, internucleosomal DNA fragmentation, and protein cleavage (Bratton and Cohen, 2001). During apoptosis enzymes with cysteine protease activity designed as “caspases” (Chang and Yang, 2000) cleave several substrates including parp-1, a DNA nick sensor that catalyzes DNA repair (Duriez and Shah, 1997; Soldani and Scovassi, 2002). After cleavage, parp-1 loses the nick sensor function and is inactive toward DNA damage. Using western blot analysis, we showed that 2l treatment induced parp-1 cleavage in all three cell lines (Figures 4A–4C).
In addition, we also investigated the effect of 2l on the activation of other apoptotic markers, in particular the bcl-2 family members, playing pivotal roles in regulating the mitochondrial apoptotic pathway. As can be seen from Figure 5, the presence of 2l decreased bcl-2 expression (Figure 5A) in all three BC cell lines. Cytosolic translocation of cytochrome c has been proposed to be an essential step.

**Figure 4. Treatment with Dihydrofurofuranone 2l Induces parp-1 Cleavage in Breast Cancer Cells**

(A–C) Cells were left untreated (-) or treated with 2l (20 µM) (+) for 48 hr. Western blot analyses of parp-1 in MCF-7 (A), MDA-MB-231 (B), and MDA-MB-468 (C) were performed on equal amounts of total proteins. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. See Transparent Methods for experimental details.

**Figure 5. Treatment with Dihydrofurofuranone 2l Modulates the Expression of Apoptotic Markers in Breast Cancer Cells**

(A and B) MCF-7, MDA-MB-231, and MDA-MB-468 breast cancer cells were left untreated (bs, –) or treated with 2l (20 µM) (2l, +) for 48 hr. Western blot analyses of bcl-2 (A) and cytochrome c (cyt c) (B) were performed on equal amounts of total proteins. GAPDH was used as a loading control. Blots are representative of three independent experiments with similar results. (A and B, upper panels) Graphs represent means of normalized optical densities from three experiments, bars represent SD (*p < 0.05 versus untreated cells [–]). See Transparent Methods for experimental details. SD, standard deviation.
in the mitochondria-dependent apoptotic pathway. In fact, cytochrome c release from mitochondria into the cytosol triggers caspase activation (Kuida et al., 1998; Wang, 2001; Wilson, 1998). Therefore, we examined if cytochrome c was released into the cytosol after treatment with 2l. Cytosolic protein fraction was isolated and analyzed by western blot analysis (Figure 5B). As reported in Figure 5B, cytochrome c levels increased in the cytosolic fraction of all three BC cell lines treated with 2l.

Conclusions

In conclusion, we have reported a novel carbonylative double cyclization approach to biologically active 6,6a-dihydrofuro[3,2-b]furan-2(5H)-ones 2 starting from simple and readily available starting materials (4-yn-1,3-diols 1, carbon monoxide, and oxygen). The process allows the formation of two cycles and three new bonds (O-C, C-C, and C-O) in one single operation and in ordered sequence. The dihydrofurofurones thus synthesized have shown a significant antitumor activity against BC cell lines. In particular, 5,5-dimethyl-6a-phenyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one 2l showed the most significant inhibitory effects on the cell vitality of tumor cells, whereas it had practically no effect on the vitality of normal cells. For 2l, molecular events leading to cell death were further investigated, and the results evidenced that this molecule was able to activate an intrinsic apoptotic mechanism.

METHODS

All methods can be found in the accompanying Transparent Methods supplemental file.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Transparent Methods, 74 figures, 2 tables, and 2 data files and can be found with this article online at https://doi.org/10.1016/j.isci.2018.04.022.

ACKNOWLEDGMENTS

We thank the University of Calabria for financial support.

AUTHOR CONTRIBUTIONS

Conceptualization, B.G., R.M. N.D.C., and V.P.; methodology, all authors; validation, R.M., I.Z., A.C., N.D.C., R.S.; investigation, I.Z., A.C., R.M., N.M.; writing, B.G. and V.P.; supervision, B.G.

DECLARATION OF INTERESTS

An Italian patent has been filed on July 13, 2017 (# 102017000078586), titled “Derivati 6,6a-diodofuro[3,2-b] furan-2-(5H)onici, loro preparazione e uso nel trattamento dei tumori.” Inventors: Bartolo Gabriele, Adele Chimento, Raffaella Mancuso, Vincenzo Pezzi, Ida Ziccarelli, Rosa Sirianni; Applicant: University of Calabria, Italy.

Received: February 20, 2018
Revised: March 23, 2018
Accepted: April 26, 2018
Published: May 25, 2018

REFERENCES

Alcaide, B., and Almendros, P. (2014). Gold-catalyzed cyclization reactions of allenol and alkylnol derivatives. Acc. Chem. Res. 47, 939–952.
Bauer, K.R., Brown, M., Cress, R.D., Parise, C.A., and Caggiano, V. (2007). Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype. Cancer 109, 1721–1728.
Beller, M., ed. (2006). Catalytic Carbonylation Reactions (Springer).
Beller, M., and Czarnetzki, B.D. (2006). Gold-catalyzed cyclization reactions of allenoids. Angew. Chem. Int. Ed. 45, 6978–6999.
Bratton, S.B., and Cohen, G.M. (2001). Apoptotic death sensor: an organelle’s alter ego? Trends Pharmacol. Sci. 22, 306–315.
Carey, L.A., Dees, E.C., Sawyer, L., Gatti, L., Moore, D.T., Collicchio, F., Ollila, D.W., Sartor, C.I., Graham, M.L., and Perou, C.M. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329.
Chang, H.Y., and Yang, X. (2000). Proteases for cell suicide: functions and regulation of caspases. Microbiol. Mol. Biol. Rev. 64, 821–846.
Debrouwer, W., Heugebaert, T.S.A., Roman, B.I., and Stevens, C.V. (2015). Homogeneous gold-catalyzed cyclization reactions of alkynes with N- and S-nucleophiles. Adv. Synth. Catal. 357, 2975–3006.
Dunne, P., and Shah, G.M. (1997). Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem. Cell Biol. 75, 337–349.
Friis, S.D., Lindhardt, A.T., and Skydstrup, T. (2016). The development and application of two-chamber reactors and carbon monoxide
precursors for safe carbonylation reactions. Acc. Chem. Res. 49, 394–405.

Gabriele, B., Mancuso, R., and Salerno, G. (2012). Oxidative carbonylation as a powerful tool for the direct synthesis of carbonylated heterocycles. Eur. J. Org. Chem. 6825–6839.

Gabriele, B., Veltri, L., Mancuso, R., and Carfagna, C. (2014). Cascade reactions: a multicomponent approach to functionalized indane derivatives by a tandem palladium-catalyzed carbamoylation/cyclocarbonylation process. Adv. Synth. Catal. 356, 2547–2558.

Gadge, S.T., and Bhanage, B.M. (2014). Recent advances in palladium-catalyzed carbonylation reactions: RSC Adv. 4, 10367–10389.

Gehr, P.H., Hirschbeck, V., Ciszek, B., and Flescher, I. (2016). Carbonylations of alkenes in the presence of alkoxycarbonylation effects: theoretical basis and synthetic examples. Chem. Rev. 116, 2977–2989.

Haffty, B.G., Yang, Q., Reiss, M., Kearney, T., Higgins, S.A., Weidhaas, J., Harris, L., Hsu, W., and Toppmeyer, D. (2006). Localregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24, 5652–5657.

Haffty, B.G., Yang, Q., Reiss, M., Kearney, T., Higgins, S.A., Weidhaas, J., Harris, L., Hsu, W., and Toppmeyer, D. (2006). Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J. Clin. Oncol. 24, 5652–5657.

Jung, M.E., and Pizzii, G. (2005). gem-disubstituent effect: theoretical basis and synthetic applications. Chem. Rev. 105, 1735–1766.

Kalick, P., and Urrutigoytia, M. (2015). Recent improvements in the alkoxy carbonylation reactions catalyzed by transition metal complexes. Inorg. Chem. Acta 421, 110–121.

Kapitán, P., and Gracz, T. (2008). Asymmetric intramolecular Pd(II)-catalysed oxocarbonylation of alkene-1,3-diols. Arkivoc 11, 8–17.

Kirkpatrick, P. (2009). Anticancer drugs: targeting triple-negative breast cancer. Nat. Rev. Drug Discov. 8, 21.

Kollár, L., ed. (2008). Modern Carbonylation Methods (Wiley-VCH).

Krause, N., and Winter, C. (2011). Gold-catalyzed nucleophilic cyclization of functionalized allenes: a powerful access to carbon- and heterocycles. Chem. Rev. 111, 1994–2009.

Kuida, K., Haydar, T.F., Gu, Y., Taya, J., Jung, M.E., and Piizi, G. (2005). Ribose) polymerase-1 cleavage during apoptosis: a personal account. Synlett 113, 84–94.

Krause, N., and Winter, C. (2011). Gold-catalyzed nucleophilic cyclization of functionalized allenes: a powerful access to carbon- and heterocycles. Chem. Rev. 111, 1994–2009.

Kuida, K., Haydar, T.F., Kuan, C.Y., Gu, Y., Taya, J., Jung, M.E., and Piizi, G. (2005). Ribose) polymerase-1 cleavage during apoptosis: a personal account. Synlett 113, 84–94.

Kunai, K., Haydar, T.F., Kuan, C.Y., Gu, Y., Taya, J., Jung, M.E., and Piizi, G. (2005). Ribose) polymerase-1 cleavage during apoptosis: a personal account. Synlett 113, 84–94.

Kunai, K., Haydar, T.F., Kuan, C.Y., Gu, Y., Taya, J., Jung, M.E., and Piizi, G. (2005). Ribose) polymerase-1 cleavage during apoptosis: a personal account. Synlett 113, 84–94.

Kunai, K., Haydar, T.F., Kuan, C.Y., Gu, Y., Taya, J., Jung, M.E., and Piizi, G. (2005). Ribose) polymerase-1 cleavage during apoptosis: a personal account. Synlett 113, 84–94.
Supplemental Information

Catalytic Double Cyclization Process
for Antitumor Agents
against Breast Cancer Cell Lines

Raffaella Mancuso, Ida Ziccarelli, Adele Chimento, Nadia Marino, Nicola Della Ca', Rosa Sirianni, Vincenzo Pezzi, and Bartolo Gabriele
**Figure S1.** ORTEP drawing of the two crystallographically independent molecules in the asymmetric unit of crystals of 2g. Thermal ellipsoids have been depicted at the 30% probability level. Note that only the (6aS) enantiomer is present in the asymmetric unit, while the (6aR) enantiomer is generated by symmetry, Related to Figure 1

**Figure S2.** ORTEP drawing of the molecular structure of (5RS,6aRS)-2j. Thermal ellipsoids have been depicted at the 30% probability level. Note that only the (5S,6aS) enantiomer is present in the asymmetric unit of crystals of 2j, while the (5R,6aR) enantiomer is generated by symmetry, Related to Figure 1 and Table 1
Figure S3. $^1$H-NMR (CDCl$_3$) of 2-(1-Hydroxycyclohexyl)-1-phenylethan-1-one, Related to Figure 1
Figure S4. $^{13}$C-NMR (CDCl$_3$) of 2-(1-Hydroxycyclohexyl)-1-phenylethan-1-one, Related to Figure 1
Figure S5. $^1$H-NMR (CDCl$_3$) of 1a, Related to Scheme 2
Figure S6. $^{13}$C-NMR (CDCl$_3$) of 1a, Related to Scheme 2
Figure S7. $^1$H-NMR (CDCl$_3$) of 1b, Related to Scheme 2
Figure S8. $^{13}$C-NMR (CDCl$_3$) of 1b, Related to Scheme 2
Figure S9. $^1$H-NMR (CDCl$_3$) of 1c, Related to Scheme 2
Figure S10. $^{13}$C-NMR (CDCl$_3$) of 1c, Related to Scheme 2
Figure S11. $^1$H-NMR (CDCl$_3$) of 1d, Related to Scheme 2
Figure S12. $^{13}$C-NMR (CDCl$_3$) of 1d, Related to Scheme 2
Figure S13. $^1$H-NMR (CDCl$_3$) of 1e, Related to Figure 1
Figure S14. $^{13}$C-NMR (CDCl$_3$) of 1e, Related to Figure 1
Figure S15. $^1$H-NMR (CDCl$_3$) of 1f, Related to Figure 1
Figure S16. $^{13}$C-NMR (CDCl$_3$) of 1f, Related to Figure 1
Figure S17. $^1$H-NMR (CDCl$_3$) of 1g, Related to Figure 1
Figure S18. $^1$C-NMR (CDCl$_3$) of 1g, Related to Figure 1
Figure S19. $^1$H-NMR (CDCl$_3$) of 1h, Related to Figure 1 and Scheme 3
Figure S20. $^{13}$C-NMR (CDCl$_3$) of 1h, Related to Figure 1 and Scheme 3
Figure S21. $^1$H-NMR (CDCl$_3$) of (2RS,4SR)-1i, Related to Figure 1 and Table 1
Figure S22. $^{13}$C-NMR (CDCl$_3$) of (2RS,4SR)-1i, Related to Figure 1 and Table 1
Figure S23. $^1$H-NMR (CDCl$_3$) of (2RS,4RS)-1i, Related to Figure 1 and Table 1
Figure S24. $^{13}$C-NMR (CDCl$_3$) of (2RS,4RS)-1i, Related to Figure 1 and Table 1
Figure S25. $^1$H-NMR (CDCl$_3$) of (2RS,4SR)-1j, Related to Figure 1 and Table 1
Figure S26. $^{13}$C-NMR (CDCl$_3$) of (2RS,4SR)-1j, Related to Figure 1 and Table 1
Figure S27. $^1$H-NMR (CDCl$_3$) of (2RS,4RS)-1j, Related to Figure 1 and Table 1
Figure S28. $^{13}$C-NMR (CDCl$_3$) of (2RS,4RS)-1j, Related to Figure 1 and Table 1
Figure S29. $^1$H-NMR (CDCl$_3$) of (2RS,4SR)-1k, Related to Figure 1 and Table 1
Figure S30. $^{13}$C-NMR (CDCl$_3$) of (2RS,4SR)-1k, Related to Figure 1 and Table 1
Figure S31. $^1$H-NMR (CDCl$_3$) of (2RS,4RS)-1k, Related to Figure 1 and Table 1
Figure S32. $^{13}$C-NMR (CDCl$_3$) of (2RS,4RS)-1k, Related to Figure 1 and Table 1
Figure S33. $^1$H-NMR (CDCl$_3$) of 1l, Related to Figure 1 and Scheme 3
Figure S34. $^{13}$C-NMR (CDCl$_3$) of 1l, Related to Figure 1 and Scheme 3
Figure S35. $^1$H-NMR (CDCl$_3$) of 1m, Related to Figure 1 and Scheme 3
Figure S36. $^{13}$C-NMR (CDCl$_3$) of 1m, Related to Figure 1 and Scheme 3
Figure S37. $^1$H-NMR (CDCl$_3$) of 2a, Related to Scheme 2
Figure S38. $^{13}$C-NMR (CDCl$_3$) of 2a, Related to Scheme 2
Figure S39. $^1$H-NMR (CDCl$_3$) of 2b, Related to Scheme 2
Figure S40. $^{13}$C-NMR (CDCl$_3$) of 2b, Related to Scheme 2
Figure S41. $^1$H-NMR (CDCl$_3$) of 2c, Related to Scheme 2
Figure S42. $^{13}$C-NMR (CDCl$_3$) of 2c, Related to Scheme 2
Figure S43. $^1$H-NMR (CDCl$_3$) of 2d, Related to Scheme 2
Figure S45. $^1$H-NMR (CDCl$_3$) of 2e, Related to Figure 1
Figure S46. $^{13}$C-NMR (CDCl$_3$) of 2e, Related to Figure 1
Figure S47. $^1$H-NMR (CDCl$_3$) of 2f, Related to Figure 1
Figure S48. $^{13}$C-NMR (CDCl$_3$) of 2f, Related to Figure 1
Figure S49. $^1$H-NMR (CDCl$_3$) of 2g, Related to Figure 1
Figure S50. $^{13}\text{C-NMR (CDCl}_3$) of 2g, Related to Figure 1
Figure S51. $^1$H-NMR (CDCl$_3$) of 2h, Related to Figure 1
Figure S52. $^{13}$C-NMR (CDCl$_3$) of 2h, Related to Figure 1
Figure S53. $^1$H-NMR (CDCl$_3$) of (SRS,6aSR)-2i, Related to Figure 1 and Table 1
Figure S54. $^{13}$C-NMR (CDCl$_3$) of (5RS,6aSR)-2i, Related to Figure 1 and Table 1
Figure S55. $^1$H-NMR (CDCl$_3$) of (5RS,6aRS)-2i, Related to Figure 1 and Table 1
Figure S56. $^{13}$C-NMR (CDCl$_3$) of (5RS,6aRS)-2i, Related to Figure 1 and Table 1
Figure S57. $^1$H-NMR (CDCl$_3$) of (5RS,6aSR)-2j, Related to Figure 1 and Table 1
Figure S58. $^1$H-NMR (CDCl$_3$) of ($RS,6aSR$)-2j, Related to Figure 1 and Table 1
Figure S59. $^1$H-NMR (CDCl$_3$) of $(5RS,6aRS)-2j$, Related to Figure 1 and Table 1
Figure S60. $^{13}$C-NMR (CDCl$_3$) of (5RS,6aRS)-2j, Related to Figure 1 and Table 1
Figure S61. $^1$H-NMR (CDCl$_3$) of (5RS,6αSR)-2k, Related to Figure 1 and Table 1
Figure S62. $^{13}$C-NMR (CDCl$_3$) of (5RS,6aSR)-2k, Related to Figure 1 and Table 1
Figure S63. $^1$H-NMR (CDCl$_3$) of (5RS,6aRS)-2k, Related to Figure 1 and Table 1
Figure S64. $^{13}$C-NMR (CDCl$_3$) of (5RS,6aRS)-2k, Related to Figure 1 and Table 1
Figure S65. $^1$H-NMR (CDCl$_3$) of 21, Related to Figure 1
Figure S66. $^{13}$C-NMR (CDCl$_3$) of 2l, Related to Figure 1
Figure S67. $^1$H-NMR (CDCl$_3$) of 2m, Related to Figure 1
Figure S68. $^{13}$C-NMR (CDCl$_3$) of 2m, Related to Figure 1
Figure S69. $^1$H-NMR (CDCl$_3$) of 3h, Related to Scheme 3
Figure S70. $^{13}$C-NMR (CDCl$_3$) of 3h, Related to Scheme 3
Figure S71. $^1$H-NMR (CDCl$_3$) of 3I, Related to Scheme 3
Figure S72. $^{13}$C-NMR (CDCl$_3$) of 3l, Related to Scheme 3
Figure S73. $^1$H-NMR (CDCl$_3$) of 3m, Related to Scheme 3
Figure S74. $^{13}$C-NMR (CDCl$_3$) of 3m, Related to Scheme 3
Table S1. Crystal data and structure refinement for compound 2g, Related to Figure 1

| Property                        | Value                        |
|--------------------------------|-----------------------------|
| Empirical formula              | C12 H20 O3 Si               |
| Formula weight                 | 240.37                      |
| Temperature                    | 296(2) K                    |
| Wavelength                     | 0.71073 Å                   |
| Crystal system                 | Monoclinic                  |
| Space group                    | P2₁/c                       |
| Unit cell dimensions           |                             |
| a                             | 10.192(4) Å, α= 90°.        |
| b                             | 24.816(8) Å, β= 102.166(18)° |
| c                             | 11.873(4) Å, γ= 90°.        |
| Volume                         | 2935.5(18) Å³               |
| Z                              | 8                           |
| Density (calculated)           | 1.088 Mg/m³                 |
| Absorption coefficient         | 0.152 mm⁻¹                  |
| F(000)                         | 1040                        |
| Crystal size                   | 0.200 x 0.140 x 0.060 mm³   |
| Theta range for data collection| 1.641 to 28.777°.           |
| Index ranges                   | -13<=h<=12, -33<=k<=33, -15<=l<=15 |
| Reflections collected          | 41809                       |
| Independent reflections        | 6861 [R(int) = 0.0452]       |
| Completeness to theta = 25.242° | 96.2 %                     |
| Refinement method              | Full-matrix least-squares on F² |
| Data / restraints / parameters | 6861 / 0 / 289              |
| Goodness-of-fit on F²          | 1.038                       |
| Final R indices [I >2sigma(I)] | R₁ = 0.0720, wR₂ = 0.1695   |
| R indices (all data)           | R₁ = 0.1303, wR₂ = 0.1916   |
| Largest diff. peak and hole    | 0.361 and -0.295 e.Å⁻³     |

* There are two independent molecules in the asymmetric unit.
### Table S2. Crystal data and structure refinement for compound (5RS,6aRS)-2j, Related to Figure 1 and Table 1

| Property                              | Value                                      |
|---------------------------------------|--------------------------------------------|
| Empirical formula                     | C16 H19 Cl O3 Si                           |
| Formula weight                        | 322.85                                     |
| Temperature                           | 296(2) K                                  |
| Wavelength                            | 0.71073 Å                                 |
| Crystal system                        | Orthorhombic                               |
| Space group                           | Pbca                                       |
| Unit cell dimensions                  |                                           |
| $a$                                    | 14.7150(17) Å                             |
| $\alpha$                               | 90°                                       |
| $b$                                    | 10.6681(12) Å                             |
| $\beta$                                | 90°                                       |
| $c$                                    | 21.569(3) Å                               |
| $\gamma$                               | 90°                                       |
| Volume                                 | 3385.9(7) Å                               |
| $Z$                                    | 8                                          |
| Density (calculated)                  | 1.267 Mg/m³                                |
| Absorption coefficient                | 0.303 mm⁻¹                                 |
| $F(000)$                               | 1360                                       |
| Crystal size                          | 0.230 x 0.170 x 0.100 mm³                  |
| Theta range for data collection       | 2.341 to 27.024°                          |
| Index ranges                          | -18<=h<=18, -13<=k<=13, -27<=l<=27         |
| Reflections collected                 | 69219                                      |
| Independent reflections               | 3661 [$R$(int) = 0.0351]                   |
| Completeness to theta = 25.242°       | 99.7 %                                     |
| Refinement method                     | Full-matrix least-squares on $F^2$         |
| Data / restraints / parameters        | 3661 / 0 / 190                             |
| Goodness-of-fit on $F^2$              | 1.045                                      |
| Final $R$ indices [$I > 2\sigma(I)$]  | $R_1 = 0.0338$, $wR_2 = 0.0910$            |
| $R$ indices (all data)                | $R_1 = 0.0421$, $wR_2 = 0.0972$            |
| Largest diff. peak and hole           | 0.240 and -0.180 e.Å⁻³                    |
TRANSPARENT METHODS

General experimental methods
Solvents and chemicals were reagent grade and used without further purification. All reactions were analyzed by TLC on silica gel 60 F254 (Merck) and by GLC (Shimadzu GC-2010) using capillary columns with polymethylsilicone +5% phenylsilicone as the stationary phase (HP-5). Column chromatography was performed on silica gel 60 (Merck, 70–230 mesh). Evaporation refers to the removal of solvent under reduced pressure. Melting points are uncorrected. $^1$H NMR and $^{13}$C NMR spectra were recorded at 25 °C on 300 or 500 MHz spectrometers (Bruker DPX Avance 300 or 500, respectively) in CDCl$_3$ solutions with Me$_4$Si as the internal standard. Chemical shifts (δ) and coupling constants (J) are given in ppm and Hz, respectively. IR spectra were taken with a JASCO FTIR 4200 spectrometer. Mass spectra were obtained using a GC-MS apparatus (Shimadzu QP-2010) at 70 eV ionization voltage. Microanalyses were carried out in our analytical laboratory (Thermo –Fischer Elemental Analyzer Flash 2000).

Preparation of substrates
Substrates 1a-m were prepared by alkynylation of the appropriate β-hydroxy ketone using an excess of the corresponding alkynylmagnesium bromide (Gabriele et al., 2012), as described below. β-Hydroxy ketones 4-hydroxybutan-2-one and 4-hydroxy-4-methylpentan-2-one were commercially available and were used without further purification. All other necessary β-hydroxy ketones were prepared as described below.

Preparation of β-hydroxy ketones. 4-Hydroxy-3,3-dimethylbutan-2-one was prepared starting from 3-methyl-2-butanone by addition of paraformaldehyde, as reported in the literature (Markó and Schevenels, 2013). β-hydroxy ketones 3-hydroxy-1-phenylbutan-1-one, 1-(4-chlorophenyl)-3-hydroxybutan-1-one, 3-hydroxy-1-p-tolybutan-1-one, 5-hydroxy-2,5-dimethylhexan-3-one, 3-hydroxy-3-methyl-1-phenylbutan-1-one, and 2-(1-hydroxycyclohexyl)-1-phenylethanone were prepared from the corresponding methyl ketones by aldol condensation with acetaldehyde, acetone, or cyclohexanone, according to literature procedures (Chopade et al., 2004; Ma et al., 2014; Martin et al., 1990; Schneider et al., 2006). 4-Hydroxy-3,3-dimethylbutan-2-one (Markó and Schevenels, 2013), 3-hydroxy-1-phenylbutan-1-one (Chopade et al., 2004), 1-(4-chlorophenyl)-3-hydroxybutan-1-one (Ma et al., 2014), 3-hydroxy-1-p-tolybutan-1-one (Martin et al., 1990), 5-
hydroxy-2,5-dimethylhexan-3-one (Schneider et al., 2006), and 3-hydroxy-3-methyl-1-phenylbutan-1-one (Schneider et al., 2006) are known compounds. Characterization data for 2-(1-hydroxycyclohexyl)-1-phenylethanone are given below.

Preparation of 4-hydroxy-3,3-dimethylbutan-2-one (Markó and Schevenels, 2013). To a solution of 3-methyl-2-butanone (8.61 g, 100.0 mmol) in TFA (7.7 mL) was added paraformaldehyde (3.0 g, 100.0 mmol). The mixture was heated at 90 °C for 10 h. After cooling to room temperature, aqueous NaHCO$_3$ (180 mL) was carefully added to the mixture, until the solution turned yellow. The aqueous layer was extracted with CH$_2$Cl$_2$ (120 mL, followed by 2 × 60 mL). The collected organic phases were dried over Na$_2$SO$_4$, filtered and concentrated. Purification over silica gel using as eluent 8:2 hexane-EtOAc provided pure 4-hydroxy-3,3-dimethylbutan-2-one as a colorless oil (4.53 g, 39%).

Preparation of other β-hydroxy ketones (Chopade et al., 2004; Ma et al., 2014; Martin et al., 1990; Schneider et al., 2006). To a stirred solution of diisopropylamine (5.57 g, 55 mmol) in anhydrous diethyl ether (150 mL) cooled to 0°C was slowly added, under nitrogen and dropwise, a 1.6 M solution of n-BuLi in hexane (34.4 mL, 55 mmol). The resulting solution was stirred for 30 min at 0 °C prior to cooling to -78°C. The appropriate methyl ketone (50 mmol; acetophenone, 6.01 g; p-chloroacetophenone, 7.73 g; p-methylacetophenone, 6.71 g; 3-methylbutan-2-one, 4.31 g) was then slowly added to this solution. The resulting solution was stirred for 1 h at 78°C prior to slow addition of the dry aldehyde or ketone (60 mmol; acetaldehyde, 2.64 g; acetone, 3.49 g; cyclohexanone, 5.89 g). Stirring was continued for 3 h at -78 °C before the reaction was quenched with saturated aqueous ammonium chloride solution (50 mL). The reaction mixture was then allowed to reach room temperature. The layers were separated, and the aqueous layer was extracted twice with diethyl ether (50 mL). The combined organic layers were dried over Na$_2$SO$_4$ and filtered, and the solvent was removed under reduced pressure. Crude products were purified by flash chromatography on silica gel using as eluent 9:1 hexane-acetone for 3-hydroxy-1-phenylbutan-1-one; 8:2 hexane-acetone for 1-(4-chlorophenyl)-3-hydroxybutan-1-one; 9:1 hexane-diethyl ether for 3-hydroxy-1-p-tolylbutan-1-one; 7:3 hexane-EtOAc for 5-hydroxy-2,5-dimethylhexan-3-one; 8:2 pentane-diethyl ether for 3-hydroxy-3-methyl-1-phenylbutan-1-one; 9:1 hexane-EtOAc for 2-(1-hydroxycyclohexyl)-1-phenylethanone.

2-(1-Hydroxycyclohexyl)-1-phenylethan-1-one. Yield: 6.44 g, starting from 6.01 g of acetophenone (59%). Colorless solid, mp = 70-71 °C, lit. 78 °C (Yasuda et al., 1998). IR (KBr): $\nu$ = 3515 (s), 2937 (m), 2851 (m), 1674 (s), 1447 (m), 1394 (m), 1311 (w), 1219 (w), 1176 (w), 1051 (w), 983 (m), 751 (m), 737 (w), 680 (m) cm$^{-1}$; $^1$H NMR (300 MHz, CDCl$_3$): $\delta$ = 7.99-7.93 (m, 2 H, aromatic),
7.63-7.53 (m, 1 H, aromatic), 7.52-7.42 (m, 2 H, aromatic), 3.89 (s, br, 1 H, OH), 3.11 [s, 2 H, CH$_2$(CO)], 1.83-1.64 (m, 4 H, cyclohexane ring), 1.64-1.37 (m, 5 H, cyclohexane ring), 1.37-1.21 (m, 1 H, cyclohexane ring); $^{13}$C NMR (75 MHz, CDCl$_3$): $\delta = 201.9, 137.6, 133.5, 128.7, 128.1, 71.0, 47.8, 37.8, 25.8, 22.0; $GC-MS: $m/z = 218$ (1) [M$^+$], 200 (7), 176 (4), 162 (18), 147 (5), 120 (27), 105 (100), 91 (3), 77 (30); anal. calcd for C$_{14}$H$_{18}$O$_2$ (218.29): C, 77.03; H, 8.31; found: C, 76.06; H, 8.32.

Preparation of 4-yn-1,3-diols 1 (Gabriele et al., 2012). To a suspension of Mg turnings (1.74 g, 71.4 mmol) in anhydrous THF (14.8 mL), maintained under nitrogen and under reflux, was added pure ethyl bromide (1.3 mL, 17.5 mmoL) to start the formation of the Grignard reagent. The remaining bromide was added dropwise in THF solution (3.9 mL, 52.5 mmoL of EtBr in 42.9 mL of THF; total amount of EtBr added 7.63 g, 70.0 mmol). The mixture was then refluxed for an additional 20 min. After cooling, the resulting solution of EtMgBr was transferred under nitrogen into a dropping funnel and added dropwise under nitrogen to a solution of the 1-alkyne (70 mmol: trimethylsilylacetylene, 6.88 g; 1-hexyne, 5.75 g; tert-butylacetylene, 5.75 g; phenylacetylene, 7.15 g) in anhydrous THF (21 mL) at 0 °C with stirring. After additional stirring at 0 °C for 15 min, the mixture was warmed to room temperature and then maintained at 40 °C for 2 h. While warm, to the solution of [trimethylsilyl)ethynyl]magnesium bromide or alkynylmagnesium bromide thus obtained was then added dropwise under nitrogen a solution of β-hydroxy ketone (28 mmol; 4-hydroxybutan-2-one, 2.47 g; 4-hydroxy-3,3-dimethylbutan-2-one, 3.25 g; 3-hydroxy-1-phenylbutan-1-one, 4.6 g; 1-(4-chlorophenyl)-3-hydroxybutan-1-one, 5.56 g; 3-hydroxy-1-p-tolylbutan-1-one, 4.99 g; 4-hydroxy-4-methylpentan-2-one, 3.25 g; 5-hydroxy-2,5-dimethylhexan-3-one, 4.04 g; 3-hydroxy-3-methyl-1-phenylbutan-1-one, 4.99 g; 2-(1-hydroxycyclohexyl)-1-phenylethanone, 6.11 g) in anhydrous THF (34 mL). The resulting mixture was stirred at 40 °C for an additional 2 h. After the mixture was cooled to room temperature, saturated NH$_4$Cl (80 mL) and EtOAc (30 mL) were sequentially added. Phases were separated, and the aqueous phase was extracted with EtOAc (3 × 80 mL). The collected organic layers were washed with brine and dried over Na$_2$SO$_4$. After filtration and evaporation of the solvent, the product was purified by column chromatography on silica gel using as eluent 8:2 hexane-EtOAc for 1a, 1f, 1i, 1j; 9:1 hexane-EtOAc for 1b, 1c, 1d; 7:3 hexane-EtOAc for 1e, 1h, 1l; 95:5 hexane-EtOAc for 1g, 1k, 1m.

3-Methylnon-4-yn-1,3-diol (1a). Yield: 3.77 g, starting from 2.47 g of 4-hydroxybutan-2-one (79%). Colorless oil. IR (film): $\nu = 3361$ (s, br), 2967 (s), 2931 (s), 2864 (m), 2235 (w), 1453 (m), 1427 (m), 1376 (m), 11330 (w), 1269 (w), 1141 (m), 1090 (m), 1053 (m), 890 (w) cm$^{-1}$; $^1$H NMR (300 MHz,
\( \text{CDCl}_3 \): \( \delta =4.19-4.07 \) (m, 1 H, HOCH\( \text{H} \)), 3.88 (dt, \( J = 11.0, 4.5, 1 \) H, HOCH\( \text{H} \)), 3.52 (s br, 2H, 2 OH), 2.21 (t, \( J = 6.9, 2 \) H, \( \equiv \text{CCH}_2 \)), 2.02-1.89 (m, 1 H, HOCH\( _2 \text{CH}_2 \)), 1.84-1.75 (m, 1 H, HOCH\( _2 \text{CH}_2 \)), 1.55-1.33 (m, 4 H, \( \text{CH}_2\text{CH}_2\text{CH}_3 \)), 1.49 (s, 3 H, MeCO\( \text{H} \)), 0.91 (t, \( J = 7.1, 3 \) H, \( \text{CH}_2\text{CH}_3 \)); \( ^{13} \text{C} \text{NMR} \) (75 MHz, \( \text{CDCl}_3 \)): \( \delta =84.5, 83.3, 68.8, 60.6, 44.1, 31.1, 30.8, 22.0, 18.3, 13.6; \) \text{GC-MS}: \( m/z = 170 \) (absent) \( [\text{M}^+] \), 155 (3), 137 (2), 125 (100), 109 (11), 91 (7), 81 (8), 73 (13), 65 (4), 55 (8); anal. calcd for C\( _{10} \)H\( _{18} \)O\( _2 \) (170.25): C, 70.55; H, 10.66; found: C, 70.68; H, 10.65.

2,4-Dimethyldec-5-yne-2,4-diol (1b). Yield: 3.22 g, starting from 3.25 g of 4-hydroxy-4-methylpentan-2-one (58%). Yellow oil. IR (film): \( \nu = 3350 \) (s, br), 2982 (s), 2936 (s), 2875 (m), 2240 (w), 1473 (m), 1417 (m), 1386 (s), 1366 (s), 1330 (m), 1289 (m), 1187 (s), 1074 (m), 896 (m) cm\(^{-1} \); \( ^1 \text{H} \text{NMR} \) (300 MHz, \( \text{CDCl}_3 \)): \( \delta = 4.16 \) (s, br, 1 H, OH), 3.41 (s br, 1 H, OH), 2.20 (t, \( J = 7.0, 2 \) H, \( \equiv \text{CCH}_2 \)), 1.97-1.82 (m, 2 H, \( \text{CH}_2\text{COH} \)), 1.53-1.32 (m, 4 H, \( \text{CH}_2\text{CH}_2\text{CH}_3 \)), 1.52 (s, 3 H, Me), 1.50 (s, 3 H, Me), 1.29 (s, 3 H, Me), 0.90 (t, \( J = 6.8, 3 \) H, \( \text{CH}_2\text{CH}_3 \)); \( ^{13} \text{C} \text{NMR} \) (75 MHz, \( \text{CDCl}_3 \)): \( \delta =85.0, 84.8, 72.2, 67.3, 52.8, 33.7, 32.4, 30.6, 29.7, 22.0, 18.4, 13.6; \) \text{GC-MS}: \( m/z = 198 \) (absent) \( [\text{M}^+] \), 183 (2), 165 (19), 151 (6), 142 (5), 138 (6), 125 (100), 109 (33), 107 (19), 93 (15), 91 (10), 81 (13), 79 (22), 69 (11), 59 (25); anal. calcd for C\( _{12} \)H\( _{22} \)O\( _2 \) (198.30): C, 72.68; H, 11.18; found: C, 72.79; H, 11.15.

2,4,7,7-Tetramethyleoct-5-yne-2,4-diol (1c). Yield: 2.67 g, starting from 3.25 g of 4-hydroxy-4-methylpentan-2-one (48%). White solid, mp 53.2-54.2 °C. IR (KBr): \( \nu = 3335 \) (m, br), 2971 (s), 2936 (m), 2868 (m), 2228 (w), 1457 (m), 1361 (m), 1266 (m), 1191 (s), 1066 (m), 983 (m), 945 (w), 893 (m), 851 (m) cm\(^{-1} \); \( ^1 \text{H} \text{NMR} \) (300 MHz, \( \text{CDCl}_3 \)): \( \delta = 3.71 \) (s, br, 1 H, OH), 1.97-1.82 (m, 2 H, \( \text{CH}_2\text{COH} \)), 1.51 (s, 3 H, Me), 1.49 (s, 3 H, Me), 1.29 (s, 3 H, Me), 1.21 (s, 9 H, t-Bu); \( ^{13} \text{C} \text{NMR} \) (75 MHz, \( \text{CDCl}_3 \)): \( \delta = 93.1, 83.1, 72.1, 67.2, 52.9, 33.7, 32.3, 30.8, 29.8, 27.3; \) \text{GC-MS}: \( m/z = 198 \) (absent) \( [\text{M}^+] \), 183 (5), 165 (55), 137 (12), 125 (100), 109 (48), 107 (71), 91 (22), 81 (21), 59 (26); anal. calcd for C\( _{12} \)H\( _{22} \)O\( _2 \) (198.30): C, 72.68; H, 11.18; found: C, 72.76; H, 11.15.

2,4-Dimethyl-6-phenylhex-5-yne-2,4-diol (1d). Yield: 3.30 g, starting from 3.25 g of 4-hydroxy-4-methylpentan-2-one (54%). White solid, mp 57-58 °C. IR (film): \( \nu = 3337 \) (s, br), 2975 (s), 2932 (m), 2235 (w), 1598 (w), 1490 (m), 1368 (m), 1297 (w), 1260 (m), 1184 (s), 1068 (m), 897 (m), 873 (m), 757 (s), 691 (s) cm\(^{-1} \); \( ^1 \text{H} \text{NMR} \) (300 MHz, \( \text{CDCl}_3 \)): \( \delta = 7.44-7.36 \) (m, 2 H, aromatic), 7.32-7.22 (m, 2 H, aromatic), 4.87 (s, br, 1 H, OH), 3.48 (s, br, 1 H, OH), 2.07-1.92 (m, 2 H, \( \text{CH}_2\text{COH} \)), 1.63 (s, 3 H, Me), 1.62 (s, 3 H, Me), 1.31 (s, 3 H, Me); \( ^{13} \text{C} \text{NMR} \) (75 MHz, \( \text{CDCl}_3 \)): \( \delta = 131.6, 128.4, 128.3, 123.3, 94.2, 84.5, 72.4, 67.8, 53.3, 33.3, 32.8, 29.9; \) \text{GC-MS}: \( m/z = 218 \) (absent) \( [\text{M}^+] \), 200 (16), 185 (38), 162 (18), 157 (7), 145 (100), 129 (96), 119 (22), 115 (21), 102 (11), 91 (34), 77 (11), 59 (19); anal. calcd for C\( _{14} \)H\( _{18} \)O\( _2 \) (218.29): C, 77.03; H, 8.31; found: C, 77.16; H, 8.34.
3-Methyl-5-(trimethylsilyl)pent-4-yne-1,3-diol (1e). Yield: 3.44 g, starting from 2.47 g of 4-hydroxybutan-2-one (66%). White solid, mp 34-35 °C. IR (KBr): ν = 3399 (s, br), 3193 (m), 2963 (w), 2168 (w), 1637 (m), 1402 (m), 1286 (w), 1247 (m), 1125 (m), 930 (m), 842 (s), 759 (m) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): δ = 4.20-4.09 (m, 1 H, HOCH\(_2\)), 3.94-3.86 (m, 1 H, HOCH\(_2\)), 3.69 (s, br, 2 H, 2 OH), 2.00-1.92 (m, 1 H, HOCH\(_2\)CH), 1.85-1.78 (m, 1 H, HOCH\(_2\)CH), 1.52 (s, 3 H, Me), 0.17 (s, 9 H, SiMe\(_3\)) ; \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): δ = 109.1, 88.1, 68.9, 60.5, 43.9, 30.7, 0.0; GC-MS: m/z = 186 (absent) [M\(^+\)], 171 (4), 153 (6), 141 (100), 125 (14), 123 (34), 101 (13), 75 (18); anal. calcd for C\(_9\)H\(_{18}\)O\(_2\)Si (186.32): C, 58.02; H, 9.74; Si,15.07; found: C, 58.05; H, 9.75; Si,15.09.

2,2,3-Trimethyl-5-(trimethylsilyl)pent-4-yne-1,3-diol (1f). Yield: 4.5 g, starting from 3.25 g of 4-hydroxy-3,3-dimethylbutan-2-one (75%). White solid, mp 45-46 °C. IR (KBr): ν = 3335 (s, br), 2963 (s), 2898 (m), 2875 (m), 2167 (m), 1474 (m), 1393 (m), 1251 (s), 1192 (w), 1145 (m), 1111 (m), 1042 (m), 935 (m), 860 (s), 842 (s), 816 (m) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): δ = 3.94 (d, J = 10.8, 1 H, HOCH\(_2\)), 3.72 (s, br, 2 H, 2OH), 3.49 (d, J = 10.8, 1 H, HOCH\(_2\)), 1.44 (s, 3 H, Me), 1.05 (s, 3 H, Me), 0.98 (s, 3H, Me), 0.17 (s, 9 H, SiMe\(_3\)) ; \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): δ = 108.9, 88.3, 75.0, 71.4, 40.8, 25.2, 21.8, 19.2, −0.05; GC-MS: m/z = 214 (absent) [M\(^+\)], 181 (35), 165 (4), 151 (10), 141 (100), 127 (8), 101 (24), 99 (23), 83 (12), 75 (36), 73 (44); anal. calcd for C\(_{29}\)H\(_{35}\)O\(_2\)Si (214.38): C, 61.63; H, 10.34; Si, 13.10; found: C, 61.76; H, 10.31; Si, 13.12.

2,4-Dimethyl-6-(trimethylsilyl)hex-5-yne-2,4-diol (1g). Yield: 2.46 g, starting from 3.25 g of 4-hydroxy-4-methylpentan-2-one (41%). White solid, mp 69-70 °C. IR (KBr): ν = 3335 (m, br), 2971 (s), 2936 (m), 2167 (m), 1408 (m), 1368 (m), 1251 (s), 1191 (s), 1066 (w), 965 (w), 932 (w), 878 (s), 843 (s) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): δ = 3.91 (s, br, 2 H, 2 OH), 1.97-1.84 (m, 2 H, CH\(_2\)COH), 1.54 (s, 3 H, Me), 1.51 (s, 3 H, Me), 1.29 (s, 3 H, Me), 0.15 (s, 9 H, SiMe\(_3\)) ; \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): δ = 110.5, 88.5, 72.4, 67.3, 52.5, 33.1, 32.5, 29.5, −0.25; GC-MS: m/z = 214 (0.2) [M\(^+\)], 199 (2), 181 (61), 143 (34), 141 (96), 138 (24), 125 (73), 123 (100), 101 (30), 99 (41), 97 (22), 83 (41), 75 (59), 73 (76); 59 (40); anal. calcd for C\(_{23}\)H\(_{22}\)O\(_2\)Si (214.38): C, 61.63; H, 10.34; Si, 13.10; found: C, 61.60; H, 10.36; Si, 13.13.

4-Isopropyl-2-methyl-6-(trimethylsilyl)hex-5-yne-2,4-diol (1h). Yield: 3.26 g, starting from 4.04 g of 5-hydroxy-2,5-dimethylhexan-3-one (48%). White solid, mp 82-83 °C. IR (KBr): ν = 3230 (s, br), 2973 (s), 2916 (m), 2875 (m), 2164 (m), 1471 (m), 1409 (m), 1249 (m), 1195 (w), 1158 (w), 1062 (m), 1018 (m), 880 (m), 840 (s), 760 (m) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): δ = 1.95-1.70 (m, 3 H, CH\(_2\) + CHMe\(_2\)), 1.54 (s, 3 H, Me), 1.30 (s, 3 H, Me), 1.03 (d, J = 6.7, 3 H, CH\(_3\)CHCH\(_3\)), 0.97 (d, J = 6.7, 3 H, CH\(_3\)CHCH\(_3\)), 0.16 (s, 9 H, SiMe\(_3\)) ; \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): δ = 108.2, 90.8, 73.9, 72.3, 48.7, 40.4,
32.6, 29.8, 17.6, 16.8, −0.2; GC-MS: m/z = 242 (absent) [M⁺], 224 (1), 209 (7), 199 (4), 181 (18), 169 (15), 151 (52), 141 (54), 125 (100), 97 (20), 83 (21), 75 (28), 73 (81), 59 (34); anal. calc for C₁₃H₂₆O₂Si (242.43): C, 64.41; H, 10.81; Si, 11.59; found: C, 64.44; H, 10.80; Si, 11.56.

4-Phenyl-6-(trimethylsilyl)hex-5-yne-2,4-diol (1i). Mixture of diastereomers, total yield: 4.12 g, starting from 4.6 g of 3-hydroxy-1-phenylbutan-1-one (56%). Column chromatography (8:2 hexane-Et₂O) gave three fractions containing pure (2RS,4SR) diastereomer (yield: 810 mg, 11%), a mixture (2RS,4SR)/(2RS,4RS) diastereomers (DR ca. 2.2, determined by ¹H NMR; total yield: 2.06 g, 28%), and pure (2RS,4RS) diastereomer (yield: 1.25 g, 17%).

(2RS,4SR) Diastereomer. White solid, mp 64−65 °C. IR (KBr): ν = 3226 (s, br), 2964 (m), 2908 (w), 2168 (m), 1447 (m), 1426 (m), 1313 (w), 1252 (m), 1086 (m), 914 (w), 893 (m), 776 (s), 759 (s), 699 (m), 669 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.68−7.59 (m, 2 H, aromatic), 7.40−7.22 (m, 3 H, aromatic), 4.66 (s, br, 1 H, OH), 4.61−4.47 (m, 1 H, CH₃), 3.63 (s, br, 1 H, OH), 1.91 (dist dd, J = 14.5, 10.0, 1 H, CHH), 1.77 (dist d, br, J = 14.5, 1 H, CHH), 1.19 (d, J = 6.2, 3 H, Me), 0.22 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 144.9, 128.2, 127.6, 125.2, 107.2, 91.1, 74.0, 67.0, 52.4, 23.8, −0.06; GC-MS: m/z = 262 (absent) [M⁺], 243 (2), 229 (4), 217 (2), 203 (100), 187 (11), 185 (8), 161 (6), 159 (4), 135 (7), 125 (5), 105 (8), 77 (4), 73 (9); anal. calcld for C₁₅H₂₂O₂Si (262.42): C, 68.65; H, 8.45; Si, 10.69.

(2RS,4RS) Diastereomer. Colorless oil. IR (film): ν = 3323 (s, br), 2966 (m), 2168 (m), 1448 (w), 1423 (w), 1251 (m), 1139 (m), 1071 (m), 840 (s), 701 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.64−7.49 (m, 2 H, aromatic), 7.45−7.24 (m, 3 H, aromatic), 3.93−3.83 (m, 1 H, CH₃), 3.72 (s, br, 1 H, OH), 3.18 (s, br, 1 H, OH), 2.19 (dist dd, J = 14.6, 9.7, 1 H, CHH), 1.99 (dist dd, J = 14.6, 1.6, 1 H, CHH), 1.11 (d, J = 6.3, 3 H, Me), 0.19 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 144.0, 128.3, 127.6, 125.3, 108.5, 90.4, 72.5, 65.0, 52.6, 23.6, −0.25; GC-MS: m/z = 262 (absent) [M⁺], 243 (1), 229 (5), 217 (1), 203 (100), 187 (10), 185 (7), 161 (7), 159 (4), 135 (8), 125 (5), 105 (10), 77 (5), 73 (10); anal. calcld for C₁₅H₂₂O₂Si (262.42): C, 68.65; H, 8.45; Si, 10.69.

4-(4-chlorophenyl)-6-(trimethylsilyl)hex-5-yne-2,4-diol (1j). Mixture of diastereomers, total yield: 5.90 g, starting from 5.56 g of 1-(4-chlorophenyl)-3-hydroxybutan-1-one (71%). Column chromatography (8:2 hexane-Et₂O) gave three fractions containing pure (2RS,4SR) diastereomer (yield: 2.50 g, 30%), a mixture (2RS,4SR)/(2RS,4RS) diastereomers (DR ca. 1.4, determined by ¹H NMR; total yield: 2.01 g, 24%), and pure (2RS,4RS) diastereomer (yield: 1.43 g, 17%).

(2RS,4SR) Diastereomer. White solid, mp 80−81 °C. IR (KBr): ν = 3203 (s, br), 2965 (m), 2912 (m), 2897 (w), 2167 (m), 1489 (m), 1425 (m), 1400 (m), 1273 (m), 1252 (m), 1160 (m), 1132 (m),...
1085 (m), 963 (m), 861 (s), 845 (s), 816 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.60-7.51 (m, 2 H, aromatic), 7.35-7.27 (m, 2 H, aromatic), 4.72 (s, br, 1 H, OH), 4.62-4.85 (m, 1 H, HOCH₂C₃H₇), 3.16 (s, br, 1 H, OH), 1.88 (dist dd, J = 14.5, 10.0, 1 H, CHH), 1.76 (dist dd, J = 14.5, 1.9, 1 H, CHH), 1.21 (d, J = 6.3, 3 H, HOCH₂C₃H₇), 0.22 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 143.9, 133.8, 128.5, 127.0, 107.4, 91.8, 73.6, 67.2, 52.9, 24.2, 0.0; GC-MS: m/z = 296 (absent) [M⁺], 278 (1), 263 (2), 251 (1), 240 (7), 237 (100), 221 (22), 219 (29), 195 (8), 169 (9), 152 (2), 139 (12), 125 (3), 111 (4), 99 (5), 75 (10), 73 (15); anal. calcd for C₁₅H₂₁ClO₂Si (296.86): C, 60.69; H, 7.13; Cl, 11.94; Si, 9.46; found: C, 60.81; H, 7.11; Cl, 11.88; Si, 9.41.

**2RS,4RS** Diastereomer. White solid, mp 75-76 °C. IR (KBr): ν = 3392 (s), 3211 (s, br), 2962 (m), 2166 (m), 1490 (m), 1404 (m), 1249 (m), 1186 (m), 1136 (s), 1008 (s), 958 (m), 895 (s), 848 (s), 816 (m), 763 (m), 726 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.54-7.44 (m, 2 H, aromatic), 7.37-7.27 (m, 2 H, aromatic), 4.17 (s, br, 1 H, OH), 3.91-3.72 (m, 1 H, CH₂C₃H₇), 3.26 (s, br, 1 H, OH), 2.18 (dist dd, J = 14.6, 9.8, 1H, CHH), 1.96 (dist d, J = 14.6, 1 H, CHH), 1.11 (d, J = 6.3, 3 H, Me), 0.19 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 142.7, 133.4, 128.4, 126.8, 108.1, 90.4, 72.1, 65.0, 52.3, 23.6, -0.25; GC-MS: m/z = 296 (absent) [M⁺], 239 (39), 237 (100), 221 (17), 219 (15), 195 (10), 169 (13), 141 (8), 139 (19), 125 (5), 111 (7), 99 (10), 83 (6), 75 (20), 73 (26); anal. calcd for C₁₅H₂₁ClO₂Si (296.86): C, 60.69; H, 7.13; Cl, 11.94; Si, 9.46; found: C, 60.73; H, 7.12; Cl, 11.91; Si, 9.47.

**4-(p-Tolyl)-6-(trimethylsilyl)hex-5-yn-2,4-diol (1k)**. Mixture of diastereomers, total yield: 3.87 g, starting from 4.99 g of 3-hydroxy-1-(p-tolyl)butan-1-one (50%). Column chromatography (8:2 hexane-Et₂O) gave three fractions containing pure (2RS,4SR) diastereomer (yield: 1.70 g, 22%), a mixture (2RS,4SR)/(2RS,4RS) diastereomers (DR ca. 1.0, determined by ¹H NMR; total yield: 1.01 g, 13%), and pure (2RS,4RS) diastereomer (yield: 1.16 g, 15%).

**2RS,4SR** Diastereomer. White solid, mp 63-64 °C. IR (KBr): ν = 3336 (m, br), 2965 (s), 2920 (m), 2167 (m), 1510 (w), 1422 (m), 1376 (m), 1311 (w), 1250 (m), 1132 (m), 1086 (m), 962 (m), 844 (s), 760 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.56-7.44 (m, 2 H, aromatic), 7.20-7.10 (m, 2 H, aromatic), 4.61-4.44 (m, 1 H, HOCH₂C₃H₇), 4.30 (s, br, 1 H, OH), 3.50 (s, br, 1 H, OH), 2.34 (s, 3 H, C₆H₄CH₃), 1.92 (dist dd, J = 14.5, 10.1, 1 H, CHH), 1.78 (dist dd, J = 14.5, 1.8, 1 H, CHH), 1.20 (d, J = 6.3, 3 H, HOCH₂C₃H₇), 0.22 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 142.1, 137.3, 128.9, 125.1, 107.3, 91.0, 73.9, 66.9, 52.4, 23.8, 21.0, -0.05; GC-MS: m/z = 276 (absent) [M⁺], 243 (2), 231 (2), 217 (100), 201 (7), 175 (4), 149 (4), 119 (9), 97 (3), 75 (6), 73 (9); anal. calcd for C₁₆H₂₄O₂Si (276.45): C, 69.51; H, 8.75; Si, 10.16; found: C, 69.54; H, 8.76; Si, 10.19.
(2RS,4RS) Diastereomer: White solid, mp 85-86 °C. IR (KBr): υ = 3335 (m, br), 2965 (m), 2921 (m), 2169 (m), 1421 (m), 1250 (m), 1089 (m), 844 (s), 770 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.50-7.42 (m, 2 H, aromatic), 7.21-7.13 (m, 2 H, aromatic), 3.99-3.85 (m, 1 H, HOC₃H₃), 3.47 (s, br, 1 H, OH), 3.10 (s, br, 1 H, OH), 2.36 (s, 3 H, C₆H₄CH₃), 2.18 (dist dd, J = 14.5, 9.6, 1 H, CHH), 1.98 (dist dd, J = 14.5, 1.7, 1 H, CHH), 1.12 (d, J = 6.3, 3 H, HOCHC₃H₃), 0.19 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 141.1, 137.4, 129.0, 125.2, 108.6, 90.3, 72.4, 64.9, 52.6, 23.6, 21.0, –0.21; GC-MS: m/z = 276 (absent) [M⁺], 243 (2), 231 (1), 217 (100), 201 (8), 175 (5), 149 (6), 125 (8), 119 (12), 97 (5), 91 (8), 75 (8), 73 (12); anal. calcd for C₁₆H₂₄O₂Si (276.45): C, 69.51; H, 8.75; Si, 10.16; found: C, 69.45; H, 8.77; Si, 10.15.

2-Methyl-4-phenyl-6-(trimethylsilyl)hex-5-yne-2,4-diol (1l). Yield: 4.49 g, starting from 4.99 g of 3-hydroxy-3-methyl-1-phenylbutan-1-one (58%). White solid, mp 80-81 °C. IR (KBr): υ = 3304 (m, br), 2968 (m), 2920 (m), 2169 (m), 1448 (w), 1250 (m), 1049 (m), 875 (m), 844 (s), 689 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 7.67-7.61 (m, 2 H, aromatic), 7.37-7.31 (m, 2 H, aromatic), 7.29-7.23 (m, 1 H, aromatic), 4.61 (s, br, 1 H, OH), 3.41 (s, br, 1 H, OH), 2.12-1.99 (m, 2 H, CH₂), 1.56 (s, 3 H, Me), 1.21 (s, 3 H, Me), 0.19 (s, 9 H, SiMe₃); ¹³C NMR (126 MHz, CDCl₃): δ = 146.1, 128.2, 127.4, 125.2, 109.0, 91.5, 72.6, 72.5, 55.2, 32.2, 29.7, –0.3; GC-MS: m/z = 276 (absent) [M⁺], 258 (1), 243 (2), 202 (100), 187 (14), 185 (30), 161 (22), 159 (14), 135 (12), 125 (11), 105 (21), 99 (8), 77 (14), 75 (17), 73 (31); anal. calcd for C₁₆H₂₄O₂Si (276.45): C, 69.51; H, 8.75; Si, 10.16; found: C, 69.45; H, 8.77; Si, 10.13.

1-(2-Hydroxy-2-phenyl-4-(trimethylsilyl)but-3-yne-1-yl)cyclohexan-1-ol (1m). Yield: 5.5 g, starting from 6.11 g of 2-(1-hydroxycyclohexyl)-1-phenylethan-1-one (62%). White solid, mp = 67-68 °C. IR (KBr): υ = 3228 (m, br), 2933 (s), 2861 (m), 2167 (m), 1458 (m), 1249 (m), 1163 (m), 1074 (w), 1031 (w), 982 (w), 972 (s), 842 (m), 700 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.69-7.62 (m, 2 H, aromatic), 7.40-7.30 (m, 2 H, aromatic), 7.30-7.20 (m, 1 H, aromatic), 4.78 (s, br, 1 H, OH), 2.94 (s, 1 H, OH), 2.94 (s, 1 H, OH), 2.21-1.82 (m, 4 H, CH₂COH + 2 H on cyclohexane ring), 1.70-1.29 (m, 8 H on cyclohexane ring) 0.19 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 146.2, 128.2, 127.4, 125.2, 109.2, 91.1, 73.8, 72.3, 53.5, 40.5, 37.7, 25.5, 22.6, 22.3, –0.3; GC-MS: m/z = 316 (absent) [M⁺], 298 (3), 283 (4), 255 (5), 203 (100), 185 (30), 161 (5), 159 (7), 135 (6), 105 (9), 73 (14); anal. calcd for C₁₉H₂₈O₂Si (316.51): C, 72.10; H, 8.92; Si, 8.87; found: C, 72.25; H, 8.90; Si, 8.84.
General procedure for the palladium-catalyzed carbonylative double cyclization leading to dihydrofurofuranones 2

A 250 mL stainless steel autoclave was charged in the presence of air with PdI$_2$ (5.0 mg, $1.39 \times 10^{-2}$ mmol), KI (11.5 mg, 6.95 $\times 10^{-2}$ mmol) and a solution of 1 (0.7 mmol; 1a, 119.2 mg; 1b, 138.8 mg; 1c, 138.8 mg; 1d, 152.8 mg; 1e, 130.4 mg; 1f, 150.1 mg; 1g, 150.1 mg; 1h, 169.7 mg; 1i, 183.7 mg; 1j, 207.8 mg; 1k, 193.5 mg; 1l, 193.5 mg; 1m, 221.6 mg) in MeOH (14 mL). The autoclave was sealed and, while the mixture was stirred, the autoclave was pressurized with CO (32 atm) and air (up to 40 atm). After being stirred at 100°C for the required time (3 h for 1e, 1f, 1g, 1h, 1l, and 1m; 5 h for 1k; 15 h for 1a, 1b, 1c, 1d, 1i, and 1j) the autoclave was cooled, degassed and opened. The solvent was evaporated and the products were purified by column chromatography on neutral alumina using as eluent hexane to hexane/EtOAc 9:1.

3-Butyl-6a-methyl-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2a). Yield: 41.2 mg, starting from 119.2 mg of 3-methylnon-4-yn-1,3-diol 1a (30%) (Scheme 2). Colorless oil. IR (film): $\nu = 2967$ (m), 2941 (m), 2864 (w), 1754 (s), 1698 (s), 1463 (w), 1402 (m), 1279 (m), 1223 (m), 1135 (w), 1069 (m), 987 (m), 864 (w) cm$^{-1}$; $^1$H NMR (300 MHz, CDCl$_3$): $\delta = 4.82$-$4.60$ (m, 2 H, C$_2$H$_2$O), 2.27-$2.02$ (m, 4 H, C$_2$H$_2$CH$_2$O + C$_2$H$_2$CH$_2$), 1.60-$1.43$ (m, 2 H, C$_2$H$_2$O), 1.54 (s, 3 H, Me), 1.40-$1.22$ (m, 2 H, C$_2$H$_2$CH$_2$), 0.91 (t, $J = 7.2$, 3 H, CH$_2$C$_2$H$_3$); $^{13}$C NMR (75 MHz, CDCl$_3$): $\delta = 182.9$, 175.1, 98.7, 82.2, 77.8, 34.8, 29.6, 23.5, 22.4, 21.8, 13.8; GC-MS: $m/z = 196$ (4) [M$^+$], 181 (28), 165 (40), 154 (28), 153 (28), 151 (61), 136 (8), 125 (100), 108 (18), 99 (17), 79 (7), 69 (8), 57 (42); anal. calcd for C$_{11}$H$_{16}$O$_3$ (196.24): C, 67.32; H, 8.22; found: C, 67.29; H, 8.24.

3-Butyl-5,5,6a-trimethyl-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2b). Yield: 72.2 mg, starting from 138.8 mg of 2,4-dimethyldec-5-yn-2,4-diol 1b (46%) (Scheme 2). Yellow oil. IR (film): $\nu = 2959$ (m), 2933 (m), 2873 (w), 1761 (s), 1695 (s), 1456 (m), 1384 (m), 1372 (w), 1286 (w), 1262 (w), 1225 (w), 1170 (s), 1070 (w), 838 (w), 773 (m), cm$^{-1}$; $^1$H NMR (300 MHz, CDCl$_3$): $\delta = 2.20$-$2.10$ (m, 3 H, CHH+ CH$_2$CH$_2$CH$_2$CH$_3$), 1.98 (dist d, $J = 12.5$, 1 H, CHH), 1.62 (s, 6 H, CH$_3$CCH$_3$), 1.56-$1.44$ (m, 2 H, CH$_2$CH$_2$CH$_3$), 1.48 (s, 3 H, Me), 1.37-$1.24$ (m, 2 H, CH$_2$CH$_2$CH$_3$), 0.91 (t, $J = 7.3$, 3 H, CH$_2$CH$_3$); $^{13}$C NMR (75 MHz, CDCl$_3$): $\delta = 181.7$, 175.2, 100.0, 97.5, 83.6, 45.5, 31.5, 29.7, 28.0, 27.2, 22.4, 21.7, 13.8; GC-MS: $m/z = 224$ (2) [M$^+$], 209 (3), 196 (16), 181 (3), 169 (72), 125 (100), 99 (7), 83 (6), 69 (3); anal. calcd for C$_{13}$H$_{20}$O$_3$ (224.30): C, 69.61; H, 8.99; found: C, 69.64; H, 8.97.
3-(tert-Butyl)-5,5,6a-trimethyl-6a-dihydrofuro[3,2-b]furan-2(5H)-one (2c). Yield: 62.8 mg, starting from 138.8 mg of 2,4,7,7-tetramethyloct-5-yn-2,4-diol 1c (40%) (Scheme 2). White solid, mp= 65-66 °C. IR (KBr): ν = 2976 (m), 2870 (w), 1753 (s), 1680 (s), 1546 (m), 1351 (s), 1298 (m), 1261 (m), 1091 (m), 991 (m), 843 (w), 777 (w), cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 2.10 (dist d, J = 12.5, 1 H, CHH), 1.95 (dist d, J = 12.5, 1 H, CHH), 1.61 (s, 3 H, Me), 1.60 (s, 3 H, Me), 1.47 (s, 3 H, Me), 1.25 (s, 9 H, t-Bu); ¹³C NMR (75 MHz, CDCl₃): δ = 179.9, 173.5, 108.2, 96.8, 82.9, 45.2, 31.4, 30.7, 28.7, 28.0, 27.4; GC-MS: m/z = 224 (4) [M⁺], 209 (10), 196 (3), 169 (25), 168 (14), 153 (54), 125 (30), 113 (7), 99 (5), 83 (10), 57 (100); anal. calcd for C₁₃H₂₀O₃ (224.30): C, 69.61; H, 8.99; found: C, 69.58; H, 9.01.

5,5,6a-Trimethyl-3-phenyl-6a-dihydrofuro[3,2-b]furan-2(5H)-one (2d). Yield: 56.4 mg, starting from 152.8 mg of 2,4-dimethyl-6-phenylhex-5-yn-2,4-diol 1d (33%) (Scheme 2). White solid, mp= 94-95 °C. IR (KBr): ν = 2979 (m), 2929 (w), 1746 (s), 1667 (s), 1449 (m), 1388 (m), 1368 (m), 1268 (m), 1200 (w), 1185 (m), 1134 (w), 1091 (m), 1071 (m), 939 (m), 781 (m), 694 (m), cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.98-7.90 (m, 2 H, aromatic), 7.43-7.34 (m, 2 H, aromatic), 7.31-7.21 (m, 2 H, aromatic), 2.24 (d, J = 12.5, 1 H, CHH), 2.10 (d, J = 12.5, 1 H, CHH), 1.74 (s, 3 H, Me), 1.73 (s, 3 H, Me), 1.53 (s, 3 H, Me); ¹³C NMR (75 MHz, CDCl₃): δ = 182.0, 172.4, 129.3, 128.4, 127.3, 126.8, 99.6, 99.2, 83.6, 45.4, 31.9, 28.0, 27.6; GC-MS: m/z = 244 (23) [M⁺], 189 (31), 188 (62), 145 (100), 133 (4), 117 (11), 89 (27), 63 (6); anal. calcd for C₁₃H₁₆O₃ (244.29): C, 73.75; H, 6.60; found: C, 73.81; H, 6.63.

6a-Methyl-3-(trimethylsilyl)-6a-dihydrofuro[3,2-b]furan-2(5H)-one (2e). Yield: 107.0 mg, starting from 130.4 mg of 3-methyl-5-(trimethylsilyl)pent-4-yn-1,3-diol 1e (72%) (Figure 1). White solid, mp = 71-72 °C. IR (KBr): ν = 2961 (w), 1741 (s), 1636 (s), 1446 (w), 1390 (m), 1302 (m), 1279 (m), 1238 (s), 1181 (m), 1141 (w), 977 (w), 845 (s), 780 (m) cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ = 4.82-4.74 (m, 1H, OCHH), 4.73-4.64 (m, 1H, OCHH), 2.28-2.19 (m, 2 H, CH₂CH₂O), 1.53 (s, 3 H, Me), 0.22 (s, 9 H, SiMe₃); ¹³C NMR (126 MHz, CDCl₃): δ = 198.2, 178.4, 95.3, 85.3, 79.4, 36.3, 25.1, –0.02; GC-MS: m/z = 212 (7) [M⁺], 197 (100), 153 (3), 141 (14), 123 (72), 105 (6), 83 (5), 75 (76), 73 (65); anal. calcd for C₁₀H₁₆O₃Si (212.32): C, 56.57; H, 7.60; Si, 13.23; found: C, 56.60; H, 7.59; Si, 13.20.

6,6a-Trimethyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2f). Yield: 149.8 mg, starting from 150.1 mg of 2,2,3-trimethyl-5-(trimethylsilyl)pent-4-yn-1,3-diol 1f (89%) (Figure 1). White solid, mp = 70-71 °C. IR (KBr): ν = 2980 (m), 1745 (s), 1638 (s), 1471 (w), 1377 (m), 1303 (m),
1241 (s), 1215 (m), 1167 (w), 1124 (m), 970 (w), 898 (w), 841 (s), 779 (w) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): \(\delta = 4.43\) (dist d, \(J = 8.9, 1\) H, CHH), 4.29 (dist d, \(J = 8.9,\) CHH), 1.45 (s, 3 H, Me), 1.17 (s, 3 H, Me), 1.02 (s, 3 H, Me), 0.23 (s, 9 H, SiMe\(_3\)); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): \(\delta = 197.7, 177.3, 94.2, 89.0, 86.9, 42.3, 20.7, 20.6, 18.1, -1.64;\) GC-MS: \(m/z = 242\) (3) [(M+2)^+] 240 (18) [M^+], 225 (100), 207 (7), 185 (7), 163 (4), 151 (24), 141 (97), 139 (11), 123 (4), 99 (8), 75 (54), 73 (98); anal. calcd for C\(_{12}\)H\(_{20}\)O\(_3\)Si (240.37): C, 59.96; H, 8.39; Si, 11.68; found: C, 59.87; H, 8.42; Si, 11.64.

5,5,6a-Trimethyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2g). Yield: 154.8 mg, starting from 150.1 mg of 2,4-dimethyl-6-(trimethylsilyl)hex-5-yne-2,4-diol \(1g\) (92%) (Figure 1). White solid, mp = 45-46 °C. IR (KBr): \(\nu = 2959\) (w), 1736 (s), 1638 (s), 1456 (w), 1381 (m), 1342 (m), 1268 (m), 1232 (s), 1200 (m), 1085 (m), 1006 (w), 961 (m), 917 (m), 848 (s), 778 (m), 731 (m); \(^1\)H NMR (300 MHz, CDCl\(_3\)): \(\delta = 2.156\) (dist d, \(J = 12.5, 1\) H, CHH), 2.00 (dist d, \(J = 12.5,\) CHH), 1.63 (s, 3 H, Me), 1.62 (s, 3 H, Me), 1.47 (s, 3 H, Me), 0.23 (s, 9 H, SiMe\(_3\)); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): \(\delta = 195.4, 176.7, 97.4, 95.3, 85.1, 45.1, 31.4, 27.9, 27.4, -1.51;\) GC-MS: \(m/z = 240\) (12) [M^+], 225 (15), 207 (20), 197 (3), 185 (14), 179 (4), 172 (4), 169 (6), 163 (7), 157 (10), 141 (42), 135 (4), 123 (3), 105 (4), 99 (29), 75 (23), 73 (100); anal. calcd for C\(_{12}\)H\(_{20}\)O\(_3\)Si (240.37): C, 59.96; H, 8.39; Si, 11.68; found: C, 59.99; H, 8.37; Si, 11.71.

6a-Isopropyl-5,5-dimethyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2h). Yield: 176.6 mg, starting from 169.7 mg of 4-isopropyl-2-methyl-6-(trimethylsilyl)hex-5-yne-2,4-diol \(1h\) (94%) (Figure 1). White solid, mp = 78-79 °C. IR (KBr): \(\nu = 2973\) (m), 1735 (s), 1626 (s), 1458 (w), 1391 (w), 1374 (w), 1333 (m), 1270 (m), 1244 (m), 1214 (m), 1144 (m), 1112 (m), 1020 (w), 919 (w), 846 (s), 774 (w), 709 (m) cm\(^{-1}\); \(^1\)H NMR (300 MHz, CDCl\(_3\)): \(\delta = 2.26\) (dist d, \(J = 12.8, 1\) H, CHH), 1.95 (heptuplet, \(J = 6.7, 1\) H, CHMe\(_2\)), 1.88 (dist d, \(J = 12.8, 1\) H, CHH), 1.60 (s, 3 H, Me), 1.46 (s, 3 H, Me), 1.14 (d, \(J = 6.7, 3\) H, CH\(_2\)CH\(_3\)), 0.84 (d, \(J = 6.7, 3\) H, CH\(_3\)CH\(_2\)CH\(_3\)), 0.23 (s, 9 H, SiMe\(_3\)); \(^{13}\)C NMR (75 MHz, CDCl\(_3\)): \(\delta = 194.0, 178.2, 99.4, 97.7, 91.2, 43.7, 35.8, 32.5, 29.4, 18.1, 16.8, -0.4;\) GC-MS: \(m/z = 268\) (2) [M^+], 253 (7), 235 (4), 225 (38), 213 (4), 197 (1), 181 (1), 167 (1), 141 (39), 135 (14), 127 (22), 99 (4), 83 (10), 75 (28), 73 (100), 71 (31); anal. calcd for C\(_{14}\)H\(_{24}\)O\(_3\)Si (268.42): C, 62.64; H, 9.01; Si, 10.46; found: C, 62.77; H, 9.04; Si, 10.51.

5-Methyl-6a-phenyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2i). Mixture of diastereomers, (5RS,6aSR)/(5RS,6aRS) DR ca. 1.9, determined by \(^1\)H NMR. Yield: 125.2 mg, starting
from 183.7 mg of 4-phenyl-6-(trimethylsilyl)hex-5-yne-2,4-diol 1i (62%) (Figure 1). Single diastereomers were formed starting from the corresponding substrate diastereomers, as reported in Table 1, entries 1 and 2.

**{(5RS,6aSR) Diastereomer.** Yield: 37.2 mg, starting from 1.8 mg of PdI$_2$ (5.0×10$^{-3}$ mmol), 4.1 mg of KI (2.5×10$^{-2}$ mmol), 5.0 mL of MeOH, and 65.2 mg (0.25 mmol) of \((2RS,4SR)\)-1i (52%) (Table 1, entry 1). Colorless oil. IR (film): ν = 2957 (m), 1748 (s), 1637 (s), 1449 (w), 1385 (w), 1359 (m), 1237 (s), 1193 (w), 1019 (m), 845 (s), 770 (m), 701 (m), 626 (w) cm$^{-1}$; $^1$H NMR (300 MHz, CDCl$_3$): δ = 7.36 (s, 5 H, aromatic), 4.89-4.74 (m, 1 H, CH), 2.73 (ddd, $J$ = 11.8, 4.0, 0.8, 1 H, CHH), 2.10 (td, $J$ = 11.8, 0.8, 1 H, CHH), 1.51 (dd, $J$ = 6.2, 0.8, 3 H, CHCH$_3$), 0.28 (s, 9 H, SiMe$_3$); $^{13}$C NMR (75 MHz, CDCl$_3$): δ = 193.0, 176.0, 138.7, 129.0, 96.4, 88.1, 87.2, 44.0, 20.7, −1.5; GC-MS: $m/z$ = 290 (2) [(M+2)$^+$], 288 (26) [M$^+$], 273 (1), 229 (18), 220 (13), 219 (11), 201 (5), 185 (5), 178 (9), 155 (21), 141 (47), 129 (5), 115 (5), 105 (17), 77 (23), 75 (24), 73 (100); anal. calcd for C$_{16}$H$_{20}$O$_3$Si (288.41): C, 66.63; H, 6.99; Si, 9.74; found: C, 66.66; H, 7.01; Si, 9.77.

**{(5RS,6aRS) Diastereomer.** Yield: 86.9 mg, starting from 3.5 mg of PdI$_2$ (9.7×10$^{-3}$ mmol), 8.1 mg of KI (4.9×10$^{-2}$ mmol), 9.8 mL of MeOH, and 129.4 mg (0.49 mmol) of \((2RS,4SR)\)-1i (61%) (Table 1, entry 2). White solid, mp = 87-88°C. IR (KBr): ν = 2957 (m), 1747 (s), 1637 (s), 1450 (w), 1366 (m), 1275 (m), 1247 (m), 1184 (m), 1090 (w), 1017 (w), 922 (m), 845 (s), 713 (m) cm$^{-1}$; $^1$H NMR (300 MHz, CDCl$_3$): δ = 7.44-7.30 (m, 5 H, Ph), 5.31-5.15 (m, 1 H, CHCH$_3$), 2.74-2.61 (m, 1 H, CHH), 2.49-2.59 (m, 1 H, CHH), 1.06 (d, $J$ = 6.9, 3 H, Me), 0.30 (s, 9 H, SiMe$_3$); $^{13}$C NMR (75 MHz, CDCl$_3$): δ = 194.5, 177.5, 142.5, 130.4, 127.9, 99.4, 90.0, 88.5, 40.7, 22.1, 0.0; GC-MS: $m/z$ = 290 (1) [(M+2)$^+$], 288 (20) [M$^+$], 273 (1), 229 (9), 220 (27), 219 (20), 214 (7), 201 (4), 185 (5), 178 (6), 155 (17), 141 (54), 129 (5), 115 (5), 105 (15), 77 (19), 75 (19) 73 (100); anal. calcd for C$_{16}$H$_{20}$O$_3$Si (288.42): C, 66.63; H, 6.99; Si, 9.74; found: C, 66.70; H, 6.95; Si, 9.77.

**6a-(4-Chlorophenyl)-5-methyl-3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (2j).** Mixture of diastereomers, \((5RS,6aSR)/(5RS,6aSR)\) DR ca. 1.8, determined by $^1$H NMR. Yield: 131.1 mg, starting from 207.8 mg of 4-(4-chlorophenyl)-6-(trimethylsilyl)hex-5-yne-2,4-diol 1j (58%) (Figure 1). Single diastereomers were formed starting from the corresponding substrate diastereomers, as reported in Table 1, entries 3 and 4.

**{(5RS,6aSR) Diastereomer.** Yield: 82.1 mg, starting from 2.7 mg of PdI$_2$ (7.5×10$^{-3}$ mmol), 6.2 mg of KI (3.7×10$^{-2}$ mmol), 7.6 mL of MeOH, and 110.4 mg (0.38 mmol) of \((2RS,4SR)\)-1j (68%) (Table 1, entry 3). White solid, mp = 84-85 °C; IR (KBr): ν = 2957 (m), 1748 (s), 1638 (s), 1493 (w), 1357 (w), 1237
Figure H.9, 20.7, 3 H, C = 7.26

13C NMR (75 MHz, CDCl3): δ = 192.6, 176.2, 136.8, 134.9, 129.1, 127.3, 95.9, 87.4, 87.3, 43.6, 20.7, –1.6; GC-MS: m/z = 322 (26) [M+], 263 (14), 253 (5), 228 (19), 219 (11), 189 (6), 177 (2), 169 (2), 154 (4), 141 (73), 111 (11), 93 (5), 75 (23), 73 (100); anal. calcd for C16H19ClO3Si (322.86): C, 59.52; H, 5.93; Cl, 10.98; Si, 8.70; found: C, 59.66; H, 5.95; Cl, 11.05; Si, 8.63.

(5RS,6aRS) Diastereomer. Yield: 58.4 mg, starting from 2.5 mg of PdI2 (6.9×10^{-3} mmol), 5.7 mg of KI (3.4×10^{-2} mmol), 7.0 mL of MeOH, and 102.5 mg (0.35 mmol) of (2RS,4RS)-1j (52%), (Table 1, entry 4). White solid, mp = 84-85 °C. IR (KBr): ν = 2957 (m), 1747 (s), 1638 (s), 1493 (w), 1243 (m), 1180 (w), 1097 (w), 1015 (w), 920 (w), 844 (s), 772 (w) cm⁻¹; 1H NMR (300 MHz, CDCl3): δ = 7.41-7.22 (m, 4 H, aromatic), 5.31-5.14 (m, 1 H, CH3), 2.74-2.60 (m, 1 H, CHH), 2.51-2.41 (m, 1 H, CHH), 1.11 (dist d, J = 6.9, 3 H, Me), 0.29 (s, 9 H, SiMe$_3$); 13C NMR (75 MHz, CDCl3): δ = 192.6, 176.2, 139.2, 134.9, 129.1, 127.8, 97.7, 88.6, 86.4, 38.9, 20.7, –1.52; GC-MS: m/z = 324 (5) [(M+2)$^+$], 322 (12) [M$^+$], 263 (4), 253 (5), 228 (9), 219 (11), 189 (3), 154 (2), 141 (69), 128 (2), 111 (8), 75 (17), 73 (100); anal. calcd for C16H19ClO3Si (322.86): C, 59.52; H, 5.93; Cl, 10.98; Si, 8.70; found: C, 59.66; H, 5.96; Cl, 11.03; Si, 8.76.

5-Methyl-6a-(p-tolyl)-3-(trimethylsilyl)-6a-dihydrofuro[3,2-b]furan-2(5H)-one (2k). Mixture of diastereomers, (5RS,6aSR)/(5RS,6aRS) DR ca. 1.8, determined by 1H NMR. Yield: 150.3 mg, starting from 193.5 mg of 4-(p-tolyl)-6-(trimethylsilyl)hex-5-yn-2,4-diol 1k (71%) (Figure 1). Single diastereomers were formed starting from the corresponding substrate diastereomers, as reported in Table 1, entries 5 and 6.

(5RS,6aSR) Diastereomer. Yield: 43.6 mg, starting from 2.6 mg of PdI2 (7.2×10^{-3} mmol), 6.0 mg of KI (3.6×10^{-2} mmol), 7.2 mL of MeOH, and 99.0 mg (0.36 mmol) of (2RS,4SR)-1k (40%) (Table 1, entry 5). Colorless oil. IR (film): ν = 2958 (m), 1747 (s), 1638 (s), 1513 (w), 1446 (w), 1358 (w), 1237 (m), 1193 (w), 1173 (w), 1068 (w), 1017 (m), 925 (m), 846 (s), 768 (m) cm⁻¹; 1H NMR (300 MHz, CDCl3): δ = 7.26-7.14 (m, 4 H, aromatic), 4.88-4.74 (m, 1 H, CH3CH3), 2.73 (dd, J = 11.8, 4.0, 1 H, CHH), 2.34 (s, 3 H, CH3C6H4), 2.09 (dist dd, J = 11.8, 10.6, 1 H, CHH), 1.51 (d, J = 6.3, 3 H, CHCH3), 0.28 (s, 9 H, SiMe$_3$); 13C NMR (75 MHz, CDCl3): δ = 193.3, 176.5, 138.8, 135.2, 129.5, 125.7, 95.5, 87.9, 87.3, 43.6, 21.1, 20.6, –1.5; GC-MS: m/z = 304 (7), [(M+2)$^+$], 303 (26) [(M+1)$^+$], 302 (100) [M$^+$], 243 (29), 228 (22), 219 (48), 201 (12), 192 (20), 177 (10), 169 (18), 141 (44), 119 (38), 91 (22), 75 (13), 73 (68); anal. calcd
for C17H22O3Si (302.45): C, 67.51; H, 7.33; Si, 9.29; found: C, 67.54; H, 7.34; Si, 9.31.

(5RS,6aRS) Diastereomer. Yield: 91.1 mg, starting from 2.7 mg of Pd2 (7.5×10⁻³ mmol), 6.2 mg of KI (3.7×10⁻² mmol), 7.6 mL of MeOH, and 103.8 mg (0.38 mmol) of (2RS,4RS)-1k (80%) (Table 1, entry 6). White solid, mp = 76-77 °C. IR (KBr): ν = 2957 (m), 1744 (s), 1637 (s), 1513 (w), 1453 (w), 1365 (m), 1270 (m), 1248 (m), 1183 (m), 1089 (w), 1058 (w), 1017 (m), 920 (w), 845 (s), 698 (w), 637 (w) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.30-7.10 (m, 4 H, aromatic), 5.28-5.14 (m, 1 H, CHCH₃), 2.65 (dist dd, J = 12.1, 9.1, 1 H, CHH), 2.53 (dist d, J = 12.1, 1 H, CHH), 2.34 (s, 3 H, CH₃C₆H₄), 1.09 (d, J = 6.9, 3 H, CHCH₃), 0.29 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 194.4, 177.6, 139.9, 138.8, 130.6, 127.3, 98.4, 89.7, 88.1, 40.0, 22.2, 21.7, –0.4; GC-MS: m/z = 304 (5), [(M+2)⁺], 303 (66) [(M+1)⁺], 302 (69) [M⁺], 287 (2), 243 (21), 234 (19), 233 (14), 228 (21), 219 (32), 211 (8), 192 (9), 169 (15), 141 (51), 119 (27), 91 (23), 75 (16), 73 (100); anal. calcd for C₁₇H₂₂O₃Si (302.45): C, 67.51; H, 7.33; Si, 9.29; found: C, 67.68; H, 7.36; Si, 9.33.

5,5-Dimethyl-6α-phenyl-3-(trimethylsilyl)-6,6α-dihydrofuro[3,2-b]furan-2(5H)-one (2l). Yield: 190.5 mg, starting from 193.5 mg of 2-methyl-4-phenyl-6-(trimethylsilyl)hex-5-yn-2,4-diol 1l (90%) (Figure 1). White solid, mp = 77-78 °C. IR (KBr): ν = 2956 (m), 1741 (s), 1697 (s), 1495 (w), 1452 (m), 1390 (m), 1377 (w), 1350 (m), 1268 (m), 1250 (m), 1196 (m), 1146 (w), 1028 (m), 1077 (w), 1055 (m), 937 (w), 847 (s), 778 (w), 705 (s), 629 (w) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.36 (s, 5 H, aromatic ring), 2.73 (dist d, J = 12.4, 1 H, CHH), 2.30 (dist d, J = 12.4, 1 H, CHH), 1.52 (s, 3 H, Me), 1.11 (s, 3 H, Me), 0.30 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 192.0, 176.0, 140.5, 128.9, 126.5, 98.2, 97.7, 88.5, 46.2, 31.1, 26.7, –1.4; GC-MS: m/z = 302 (18) [M⁺], 269 (1), 247 (7), 234 (9), 219 (5), 201 (9), 185 (3), 178 (16), 169 (5), 161 (20), 141 (67), 129 (5), 115 (4), 105 (45), 77 (21), 75 (16), 73 (100); anal. calcd for C₁₇H₂₂O₃Si (302.44): C, 67.51; H, 7.33; Si, 9.29; found: C, 67.54; H, 7.34; Si, 9.31.

3α'-Phenyl-6'-[(trimethylsilyl)-3'H-spirocyclohexane-1,2'-furo[3,2-b]furan]-5'(3α'H)one (2m). Yield: 167.8 mg, starting from 221.6 mg of 1-(2-hydroxy-2-phenyl-4-(trimethylsilyl)but-3-yn-1-yl)cyclohexan-1-ol 1m (70%) (Figure 1). White solid, mp = 102-103 °C. IR (KBr): ν = 2940 (m), 2861 (w), 1740 (s), 1635 (s), 1449 (w), 1372 (w), 1284 (w), 1249 (m), 1193 (w), 1057 (w), 929 (w), 840 (s), 776 (w), 702 (s), cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.35 (s, br, 5 H, aromatic), 2.78 (d, J = 12.4, 1 H, CHH), 2.16 (d, J = 12.4, 1 H, CHH), 1.88-1.13 (m, 10 H, cyclohexane ring), 0.31 (s, 9 H, SiMe₃); ¹³C NMR (75 MHz, CDCl₃): δ = 192.1, 176.4, 140.4, 128.85, 129.8, 126.3, 100.1, 97.9, 87.8, 44.5, 39.9, 35.2, 24.7, 28.8, –1.4; GC-MS: m/z = 344 (1) [(M+2)⁺], 342 (17) [M⁺], 309 (1), 283 (6), 249 (21), 248
(100), 247 (81), 232 (10), 219 (10), 201 (47), 178 (6), 141 (31), 105 (72), 77 (23), 73 (89); anal. calcd for C_{20}H_{26}O_{3}Si (342.5): C, 70.13; H, 7.65; Si, 8.20; found: C, 70.25; H, 7.68; Si, 8.17.

**General procedure for the desilylation of crude 3-(trimethylsilyl)-6,6a-dihydrofuro[3,2-b]furan-2(5H)-ones 2h, 2l, and 2m leading to 6,6a-dihydrofuro[3,2-b]furan-2(5H)-ones 3**

Substrates 1h, 1l, and 1m (0.7 mmol) were allowed to react under oxidative carbonylation conditions according to the procedure described above. To the crude reaction mixture, dried under vacuum and then diluted again with THF (7 mL), was added TBAF nH_{2}O (201.3 mg, 0.77 mmol). The resulting mixture was allowed to stir at room temperature for 2 h. The solvent was evaporated, and the residue taken up with Et_{2}O (40 mL) and washed with water (40 mL). The aqueous layer was extracted with Et_{2}O (3 × 40 mL), and the collected organic phases were dried over Na_{2}SO_{4}. After filtration, the solvent was evaporated and the products were purified by column chromatography on neutral alumina to give pure 6,6a-dihydrofuro[3,2-b]furan-2(5H)-one derivatives 3h, 3l, and 3m (eluent: from hexane to hexane/EtOAc 9:1).

**6a-Isopropyl-5,5-dimethyl-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (3h).** Yield: 116.8 mg, starting from 169.7 mg of 4-isopropyl-2-methyl-6-(trimethylsilyl)hex-5-yne-2,4-diol 1h (85%) (Scheme 3). White solid, mp= 65-66 °C. IR (KBr): ν = 2974 (m), 1759 (s), 1455 (w), 1350 (w), 1287 (w), 1214 (m), 1138 (w), 1009 (w), 887 (m), 808 (m), 782 (w), 742 (m) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 5.05 (s, 1H, =CH), 2.37 (dist d, J = 12.8, 1 H, CH₃), 2.02 (heptuplet, J = 6.8, 1 H, CH₃Me₂), 1.96 (distorted d, J = 12.8, 1 H, CHH), 1.62 (s, 3 H, Me), 1.51 (s, 3 H, Me), 1.16 (d, J = 6.8, 3 H, CH₃CHCH₃), 0.89 (d, J = 6.7, 3 H, CH₃CHCH₃); ¹³C NMR (75 MHz, CDCl₃): δ = 185.8, 174.5, 98.1, 90.7, 89.6, 42.8, 34.7, 31.6, 28.3, 17.0, 15.7; GC-MS: m/z = 196 (5) [M⁺], 168 (6), 153 (100), 141 (10), 111 (3), 83 (60), 71 (40), 69 (53); anal. calcd for C_{11}H_{16}O₃: C, 67.32; H, 8.22; found: C, 67.53; H, 8.20.

**5,5-Dimethyl-6a-phenyl-6,6a-dihydrofuro[3,2-b]furan-2(5H)-one (3l).** Yield: 127.3 mg, starting from 193.5 mg of 2-methyl-4-phenyl-6-(trimethylsilyl)hex-5-yne-2,4-diol 1l (79%) (Scheme 3). White solid, mp= 129-130 °C. IR (KBr): ν = 2980 (w), 1766 (s), 1651 (s), 1451 (w), 1352 (m), 1267 (m), 1193 (w), 1128 (m), 1055 (m), 937 (m), 806 (m), 703 (s) cm⁻¹; ¹H NMR (300 MHz, CDCl₃): δ = 7.46-7.31 (m, 5 H, aromatic), 5.20 (s, 1 H, =CH), 2.79 (dist d, J = 12.4, 1 H, CHH), 2.39 (dist d, J = 12.4, 1 H, CHH),
3a'-Phenyl-3'H-spiro[cyclohexane-1,2'-furo[3,2-b]furan]-5'(3a'H)-one (3m). Yield: 115.4 mg, starting from 221.6 mg of 1-(2-hydroxy-2-phenyl-4-(trimethylsilyl)but-3-yn-1-yl)cyclohexan-1-ol 1m (61%) (Scheme 3). White solid, m.p. = 126-127 °C. IR (KBr): ν = 2937 (m), 2862 (w), 1771 (s), 1655 (s), 1498 (w), 1449 (m), 1284 (w), 1249 (m), 1214 (m), 1128 (w), 1012 (m), 881 (m), 805 (m), 767 (w), 707 (m) cm⁻¹; 1H NMR (300 MHz, CDCl₃): δ = 7.44-7.30 (m, 5 H, Ph), 5.21 (s, 1 H, =CH), 2.85 (dist d, J = 12.4, 1 H, CHH), 2.24 (d, J = 12.4, 1 H, CHH), 1.92-1.62 (m, 3 H, cyclohexane ring), 1.62-1.10 (m, 7 H, cyclohexane ring); 13C NMR (75 MHz, CDCl₃): δ = 185.0, 173.7, 140.0, 129.1, 128.9, 126.3, 101.8, 89.1, 88.4, 44.5, 39.9, 35.2, 24.6, 22.88, 22.82; GC-MS: m/z = 270 (3) [M⁺], 201 (15), 176 (100), 141 (2), 120 (7), 105 (84), 95 (23), 81 (11), 77 (30); anal. calcd for C₁₄H₁₄O₃: C, 73.03; H, 6.13; found: C, 73.27; H, 6.11.

X-Ray crystallographic data collection and structure refinement for compounds 2g and (5RS,6αRS)-2j

Single-crystal X-ray diffraction data for compounds 2g and (5RS,6αRS)-2j were collected at room temperature on a Bruker-Nonius X8APEXII CCD area detector diffractometer using graphite-monochromated Mo-Kα radiation (λ = 0.71073 Å). Suitable, irregular colorless (2g) and pale yellow [(5RS,6αRS)-2j] crystals of approximate dimensions 0.20 × 0. 14 × 0.06 and 0.23 × 0.17 × 0.10 mm³, respectively, were selected for data collection. The data were processed through the SAINT reduction (SAINT, 2003) and SADABS multi-scan absorption (Sheldrick, 2003) software. The structures were solved with the ShelXS structure solution program. In both cases, the model was refined by using version 2013/4 of ShelXL against F² on all data by full-matrix least squares (Sheldrick, 2008; SHELXTL, 2013). The final geometrical calculations and the graphical manipulations were performed using the XP utility within the SHELXTL software. ORTEP drawings of 2g and (5RS,6αRS)-2j are given in Figures S1 and S2 while details of the crystal data/data collection/structure refinement are listed in Tables S1 and S2. Crystallographic data (excluding structure factors) for the structures reported in this paper have been deposited within the
Cell cultures, assessment of cell viability, Western blot analysis, cytochrome c detection, TUNEL assay, and statistical analyses

**Cell cultures.** All different cell lines were obtained from American Type Culture Collection (ATCC), Manassas, VA, USA. Human adenocarcinoma breast cells MCF-7 were maintained in DMEM-F12 (Dulbecco's Modified Eagle's Medium (DME) and Ham's F-12 Nutrient Mixture) containing 5% newborn calf serum (NCS), 1% glutamine, 1% penicillin/streptomycin, all from Sigma-Aldrich). MDA-MB-231 and MDA-MB-468 TNBC cells were cultured in DMEM-F12 (Dulbecco's Modified Eagle's Medium (DME) and Ham's F-12 Nutrient Mixture) containing 10% heat inactivated fetal bovine serum (FBS), 1% glutamine, 1% penicillin/streptomycin, all from Sigma-Aldrich (Sigma–Aldrich). Murine immortalized fibroblast 3T3L-1 cells were cultured in DMEM (Dulbecco's Modified Eagle's medium) containing 10% heat inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin, all from Sigma-Aldrich. Human mammary epithelial cells MCF-10A, were maintained in DMEM-F12 supplemented with 5% horse serum (HS), 1% glutamine, 1% penicillin/streptomycin, 5 μg/mL insulin, 0.25 mg/mL hydrocortisone, 20 ng/ml hEGF (human epidermal growth factor) and 0.05 mg/mL cholera enterotoxin (Sigma–Aldrich). All cell cultures were maintained at 37 °C in a humidified 5% CO₂ atmosphere and were screened periodically for mycoplasma contamination.

**Assessment of cell viability.** Cells were seeded on 48 well plates (0.25 10⁵ cells/well) and grown for 72 h in complete medium before being treated for 72 h with different doses (1, 5, 10, 20, 40 μM) of dihydrofurofuranones 2d, 2e, 2g, 2l, and 3l. The effect of the different concentrations of all different compounds was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as previously described (Caruso et al., 2012; Chimento et al., 2013; Chimento et al., 2014; Chimento et al., 2015a; Chimento et al., 2015b; Sala et al., 2013). Seventy two hours after treatments, fresh MTT, resuspended in phosphate-buffered saline (PBS), was added to each well (final concentration 0.33 mg/mL). After 3 h incubation, cells were lysed with 200μL of DMSO. Each
An experiment was performed in triplicate and the optical density was measured at 570 nm in a spectrophotometer.

**Western blot analysis.** Cells were cultured in complete medium for 48 h in 60 mm dishes (1 x 10^6 cells) before being treated for 48 h with 2l (20 μM). Methods for protein extraction and blots preparation have been previously published (Casaburi et al., 2015). Briefly, blots were incubated overnight at 4°C with (a) anti-bcl-2 (1:500), (c) anti-cytochrome c (cyt c) (1:1000), (d) anti-parp-1 (1:1000) antibodies. Membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies, and immunoreactive bands were visualized with the ECL Western blotting detection system (Amersham Bioscience). To assure equal loading of proteins, membranes were stripped and incubated overnight with an anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody (1:1000).

**Cytochrome c detection.** Cells were treated for 48 h with 2l (20 μM), fractioned and processed for cytochrome c detection as previously reported (Chimento et al., 2012). Briefly, cells were harvested by centrifugation at 2500 rpm for 10 min at 4°C. Pellets were resuspended in 50 μL of sucrose buffer (250 mM sucrose; 10 mM Hepes; 10 mM KCl; 1.5 mM MgCl2; 1 mM EDTA; 1 mM EGTA) (all from Sigma-Aldrich, Milano, Italy) containing 20 μg/mL aprotinin, 20 μg/mL leupeptin, 1 mM PMSF and 0.05% digitonine (Sigma-Aldrich). Cells were incubated for 20 min at 4°C and then centrifuged at 13,000 rpm for 15 min at 4°C. Supernatants containing cytosolic protein fraction were transferred to new tubes. Equal amounts of proteins were resolved by 15 % SDS/polyacrylamide gel and subjected to western blot analysis.

**Statistical analyses.** All experiments were performed at least three times and the results were from representative experiments. Data were expressed as mean values ± standard deviation (SD), statistical significance between control (basal) and treated samples were analyzed using GraphPad Prism 5.0 (GraphPad Software, Inc.; La Jolla, CA) software. Control and treated groups were compared using the analysis of variance (ANOVA) with Bonferroni or Dunn’s post hoc testing. A comparison of individual treatments was also performed, using Student’s t test. Significance was defined as p < 0.05.
Data and software availability

The crystallography data have been deposited at the Cambridge Crystallographic Data Center (CCDC) under accession numbers CCDC: 1566032 (2g) and 1566033 [(5RS,6aRS)-2], and can be obtained free of charge from www.ccdc.cam.ac.uk/getstructures.

SUPPLEMENTAL REFERENCES

Caruso, A., Chimento, A., El-Kashef, H., Lancelot, J.-C., Panno, A., Pezzi, V., Saturnino, C., Sinicropi, M. S., Sirianni, R., and Rault, S. (2012). Antiproliferative activity of some 1,4-dimethylcarbazoles on cells that express estrogen receptors: part I. J. Enzyme Inhib. Med. Chem. 27, 609-613.

Casaburi, I., Avena, P., De Luca, A., Chimento, A., Sirianni, R., Malivindi, R., Rago, V., Fiorillo, M., Domanico, F., Campana, C., Cappello, A. R., Sotgia, F., Lisanti, M. P., and Pezzi, V. (2015). Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC). Oncotarget 6, 25135-25148.

Chimento, A., Sirianni, R., Casaburi, I., Ruggiero, C., Maggiolini, M., Andò, S., and Pezzi, V. (2012). 17β-Estradiol activates GPER- and ESR1-dependent pathways inducing apoptosis in GC-2 cells, a mouse spermatocyte-derived cell line. Mol. Cell Endocrinol. 355, 49-59.

Chimento, A., Sala, M., Gomez-Monterrey, I. M., Musella, S., Bertamino, A., Caruso, A., Sinicropi, M. S., Sirianni, R., Puoci, F., Parisi, O. I., Campana, C., Martire, E., Novellino, E., Saturnino, C., Campiglia, P., and Pezzi, V. (2013). Biological activity of 3-chloro-azetidin-2-one derivatives having interesting antiproliferative activity on human breast cancer cell lines. Bioorg. Med. Chem. Lett. 23, 6401-6405.

Chimento, A., Casaburi, I., Rosano, C., Avena, P., De Luca, A., Campana, C., Martire, E., Santolla, M. F., Maggiolini, M., Pezzi, V., and Sirianni, R. (2014). Oleuropein and hydroxytyrosol activate GPER/ GPR30-dependent pathways leading to apoptosis of ER-negative SKBR3 breast cancer cells. Mol. Nutr. Food Res. 58, 478-489.

Chimento, A., Saturnino, C., Iacopetta, D., Mazzotta, R., Caruso, A., Plutino, M. R., Mariconda, A., Ramunno, A., Sinicropi, M. S., Pezzi, V., and Longo, P. (2015a). Inhibition of human topoisomerase I and II and antiproliferative effects on MCF-7 cells by new titanocene complexes. Bioorg. Med. Chem. 23, 7302-7312.

Chimento, A., Sirianni, R., Casaburi, I., Zolea, F., Rizza, P., Avena, P., Malivindi, R., De Luca, A., Campagna, C., Martire, E., Domanico, F., Fallo, F., Carpinelli, G., Cerquetti, L., Amendola, D., Stigliano, A., and Pezzi, V. (2015b). GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo. Oncotarget. 6, 19190-19203.

Chopade, P. R., Davis, T. A., Prasad E., and Flowers, R. A. (2004). Solvent-dependent diastereoselectivities in reductions of β-hydroxyketones by SmI2. Org. Lett. 6, 2685-2688.

Gabriele, B., Mancuso, R., Maltese, V., Velti, L., and Salerno, G. (2012). Synthesis of furan-3-carboxylic and 4-methylene-4,5-dihydrofuran-3-carboxylic esters by direct palladium iodide catalyzed oxidative carbonylation of 3-yn-1,2-diol derivatives. J. Org. Chem. 77, 8657-8668.
Ma, X., Li, Z., Liu, F., Cao, S., and Rao, H. (2014). Tetra-n-butylammonium bromide: a simple but efficient organocatalyst for alcohol oxidation under mild conditions. Adv. Synth. Catal. 356, 1741-1746.

Markó, I. M., and Schevenels, F. T. (2013). Anionic cascade reactions. One-pot assembly of (Z)-chloro-exo-methylenetetrahydrofurans from β-hydroxyketones. Belstein J. Org. Chem. 9, 1319-1325.

Martin, V. A., Murray, D. H., Pratt, N. E., Zao, Y. B., and Albizati, K. F. (1990). J. Am. Chem. Soc. 112, 6965-6878.

SAINT, version 6.45, Bruker Analytical X-ray Systems, Madison, WI, 2003.

Sala, M., Chimento, A., Saturnino, C., Gomez-Monterrey, I. M., Musella, S., Bertamino, A., Milite, C., Sinicropi, M. S., Caruso, A., Sirianni, R., Tortorella, P., Novellino, E., Campiglia, P., and Pezzi, V. Synthesis and cytotoxic activity evaluation of 2,3-thiazolidin-4-one derivatives on human breast cancer cell lines (2013). Bioorg. Med. Chem. Lett. 23, 4990-4995.

Schneider, C., Hansch M., and Weide, T. (2006). The Zirconium alkoxide-catalyzed aldol-Tishchenko reaction of ketone aldols. Chem. Eur. J. 11, 3010-3021.

Sheldrick, G. M. (2003). SADABS Program for absorption correction, version 2.10, Analytical X-ray Systems, Madison, WI.

Sheldrick, G. M. (2008). A short history of SHELX. Acta Cryst. A64, 112-122.

SHELXTL-2013/4 (2013). Bruker Analytical X-ray Instruments, Madison, WI.

Yasuda, M., Hayashi, K., Katoh, Y., Shibata, I., and Baba, A. (1998). Highly controlled chemoselectivity of tin enolate by its hybridization state. Anionic complex of tin enolate coordinated by tetrabutylammonium bromide as halo selective reagent. J. Am. Chem. Soc. 120, 715-721.